5, 6, 7, 8-tetrahydrofuran [3, 4-g] isoquinoline-3 (1H)-ketone compound as well as preparation method, pharmaceutical composition and application thereof

By synthesizing novel 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one compounds, the adverse reactions and selectivity problems of existing MAO-B inhibitors have been solved, achieving effective inhibition of MAO-B and MAO-A, which can be used to treat neuropsychiatric diseases such as Parkinson's disease and other related diseases.

CN118930553APending Publication Date: 2024-11-12INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310527554.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing MAO-B inhibitors may cause adverse reactions such as liver toxicity and hypertension, and have low selectivity, making them difficult to effectively treat neuropsychiatric diseases such as Parkinson's disease.

Method used

A novel 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one compound was designed and synthesized. Through a specific synthetic route, a compound with significant inhibitory activity against MAO-B and partial inhibitory activity against MAO-A was prepared for use in the preparation of pharmaceutical compositions.

Benefits of technology

It provides effective inhibition of MAO-B and/or MAO-A, reduces dopamine metabolism, increases dopamine levels in the brain, improves Parkinson's symptoms, reduces oxidative damage, and has potential neuroprotective effects. It is suitable for the treatment of neuropsychiatric disorders, metabolic diseases, cardiovascular diseases, and cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930553A_ABST
    Figure CN118930553A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicinal chemistry, and discloses a 5, 6, 7, 8-tetrahydrofuran [3, 4-g] isoquinoline-3 (1H)-ketone MAO inhibitor with a new structure, and a preparation method, a pharmaceutical composition and application thereof. Specifically, the invention relates to a 5, 6, 7, 8-tetrahydrofuran [3, 4-g] isoquinoline-3 (1H)-ketone compound with a new structure as shown in a formula I, a pharmaceutically acceptable salt thereof, a preparation method of the compound, a composition containing one or more of the compounds, and application of the compounds in inhibition of monoamine oxidase B / A (MAO-B / A) and treatment of MAO-B / A related diseases, especially in treatment of MAO-B / A related diseases, such as MAO-B / A, MAO-B / A related diseases, MAO-B / A related diseases, MAO-B / A related diseases, MAO-B / A related diseases, MAO-B / A related diseases and MAO-B / A related diseases. The invention also relates to application of the compound in preparation of medicines for preventing and / or treating neuropsychiatric system diseases, cardiovascular system diseases, metabolic diseases or cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology and relates to a novel structural 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one compound as shown in formula I, a pharmaceutically acceptable salt thereof and a preparation method thereof, a composition containing one or more such compounds, and uses of such compounds in inhibiting monoamine oxidase B / A (MAO-B / A) and treating diseases related to MAO-B / A, and in preparing, preventing and / or treating drugs for neuropsychiatric diseases, cardiovascular diseases, metabolic diseases or cancer. Background Art

[0002] Monoamine oxidase (MAOs) is a flavin enzyme with flavin adenine dinucleotide FAD as a coenzyme. It is located on the outer membrane of mitochondria and can catalyze the oxidative deamination reaction of endogenous (neurotransmitters) and exogenous monoamines [Advances in Experimental Medicine and Biology, 1982, 148: 141-153]. Studies have shown that MAOs play an important role in the central and peripheral nervous systems (CNS and PNS) by regulating the levels of monoamine neurotransmitters [Med Res Rev. 2019; 39: 1603-1706]. MAOs include two subtypes, MAO-A and MAO-B, both of which are distributed in most tissues of mammals and can participate in the metabolism of monoamine neurotransmitters, but they have certain differences in tissue cell distribution, substrate selectivity, and inhibitor sensitivity [Prog Nucleic Acid Res Mol Biol. 2001; 65: 129-56]. In terms of tissue distribution, MAO-A and MAO-B are distributed in different areas of the brain. MAO-A is mainly located in neurons in catecholamine-rich areas, including the substantia nigra, locus coeruleus, subcoeruleus nucleus and periventricular area of ​​the hypothalamus, while MAO-B is mainly located in serotonergic neurons and astrocytes, including the dorsal raphe nucleus and supracentral nucleus [Neuroscience. 1988 May; 25(2): 439-56]. In terms of substrate specificity, MAO-A has a higher affinity for 5-hydroxytryptamine (5-HT), while MAO-B has a higher affinity for benzylamine (BA) and phenylethylamine (PEA). Catecholamines such as dopamine (DA), epinephrine (E), noradrenaline (NE) and tyramine are common substrates of both MAOA and MAOB subtypes [British Journal of Pharmacology (2006) 147, S287–S296]. These monoamine substrates can be oxidized and deaminated to generate aldehydes, ammonia and hydrogen peroxide under the action of MAO-A and / or MAO-B. Reactive oxygen species (ROS) related to hydrogen peroxide play an important role in degenerative diseases and chronic diseases related to aging [Chem Res Toxicol, 2008, 21(1): 172-188].

[0003] Studies have shown that the main pathological changes of Parkinson's disease are the significant loss of dopaminergic neurons in the substantia nigra and the significant decrease in dopamine content in the striatum. In addition, the activity of MAO-B in the substantia nigra of Parkinson's patients is significantly enhanced. Therefore, inhibiting the activity of MAO-B can reduce the metabolism of dopamine, increase the dopamine content in the patient's brain, improve Parkinson's symptoms, and at the same time reduce the reactive oxygen species produced by the oxidation reaction catalyzed by MAO-B that damage cells, and has a potential neuroprotective effect [Advanced drug delivery reviews, 2008, 60 (13-14): 1527-1533]. MAO-B inhibitors can be used to treat neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. At present, selective MAO-B inhibitors have become one of the strategies for treating various neurodegenerative diseases such as Parkinson's disease, and can also be used to treat diseases such as depression and anxiety.

[0004] So far, three structural types of MAO-B selective inhibitors have been approved for the treatment of neurological or psychiatric diseases [Current Medicinal Chemistry, 2004, 11 (15): 2033-2043]. These include the irreversible MAO-B inhibitors selegiline and rasagiline, which can be used alone to treat early Parkinson's disease (PD) or in combination with levodopa to treat mid- to late-stage PD [Neuropsychopharmacology (2015) 40, 650–657; Molecular Neurodegeneration 2007, 2: 13]. The reversible MAO-B inhibitor safinamide (SAF) is approved for use in combination with levodopa or DA agonists to treat motor complications in patients with mid- to late-stage or early-stage PD, respectively [Drugs. 2015Apr; 75 (6): 705-11]. However, irreversible MAO inhibitors may cause adverse reactions such as liver toxicity and hypertension, while reversible inhibitors are potentially safe and effective therapeutic drugs [Journal of Medicinal Chemistry, 2004, 47(7): 1760-1766]. Therefore, finding new structural types of MAO-B reversible inhibitors has important clinical application value and is an important way to obtain new drugs for the treatment of neuropsychiatric diseases such as Parkinson's disease.

[0005] Inhibiting the activity of MAO-A and / or MAO-B is an important strategy and means for treating mental and nervous system diseases, including depression, anxiety, Parkinson's disease, Alzheimer's disease, epilepsy and other diseases; it is also a potential treatment for metabolic diseases such as obesity; cardiovascular diseases such as chronic obstructive pulmonary disease, pulmonary hypertension, heart failure, etc.; or cancer [Ageing Research Reviews, 2021, 66, 101256]. Therefore, new structural MAO-A and MAO-B inhibitors have important clinical significance, especially selective MAO-B inhibitors for the treatment of Parkinson's disease, which have been used in clinical practice.

[0006] This patent design synthesizes a new structure of 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one compounds, which have stronger inhibitory activity against MAO-B than or equivalent to MAO-A, providing a new material basis for the treatment of diseases related to MAO-B and / or MAO-A. Summary of the invention

[0007] The technical problem solved by the present invention is to provide 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one compounds and physiologically acceptable salts thereof as shown in formula I, preparation methods and pharmaceutical compositions thereof, and use thereof in preparing MAO-B and / or MAO-A inhibitors and potential drugs thereof, and use thereof in preparing drugs for treating neuropsychiatric diseases, metabolic diseases, cardiovascular diseases or cancer.

[0008] In order to solve the technical problem of the present invention, the present invention provides the following technical solutions:

[0009] The first aspect of the technical solution of the present invention is to provide a 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one derivative or a physiologically acceptable salt thereof as shown in general formula I:

[0010]

[0011] In Formula I,

[0012] Ar is selected from:

[0013] (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures:

[0014]

[0015] The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)n NRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; wherein the halogen is selected from F; the heteroatom is selected from N, O, S;

[0016] (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures:

[0017]

[0018] wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R5 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F;

[0019] R1 and R2 are independently selected from H, C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)mCH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein Rw1, Rw2, and Rw3 are independently selected from C1, C2, C3, and C4 straight chain or branched alkyl, and halogen-substituted C1, C2, C3, and C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, and 4; m is selected from 0, 1, and 2; o is selected from 1, 2, 3, 4, and 5; and X is selected from CH2, NH, and O.

[0020] The second aspect of the technical solution of the present invention is to provide a 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one derivative or a physiologically acceptable salt thereof as shown in the general formula IA:

[0021]

[0022] In Formula IA,

[0023] Ar is selected from:

[0024] (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures:

[0025]

[0026] The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, ( CH2)nNRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; wherein the halogen is selected from F;

[0027] (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures:

[0028]

[0029] wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R6 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F.

[0030] The third aspect of the technical solution of the present invention is to provide a 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one derivative or a physiologically acceptable salt thereof as shown in the general formula IB:

[0031]

[0032] In Formula IB,

[0033] Ar is selected from:

[0034] (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures:

[0035]

[0036] The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; wherein the halogen is selected from F;

[0037] (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures:

[0038]

[0039] wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R6 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F;

[0040] R7 is selected from:

[0041] C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)m CH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein said Rw1, Rw2, Rw3 are independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, 4; m is selected from 0, 1, 2; o is selected from 1, 2, 3, 4, 5; X is selected from CH2, NH, O. The fourth aspect of the technical solution of the present invention is to provide a 5, 6, 7, 8-tetrahydrofuran [3, 4-g] isoquinolin-3 (1H) -one derivative or a physiologically acceptable salt thereof as shown in the general formula IC:

[0042]

[0043] In the IC,

[0044] Ar is selected from:

[0045] (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures:

[0046]

[0047] The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; wherein the halogen is selected from F;

[0048] (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures:

[0049]

[0050] wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R6 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F;

[0051] R8 is selected from:

[0052] C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)m CH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein said Rw1, Rw2, Rw3 are independently selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen substituted C1, C2, C3, C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, 4; m is selected from 0, 1, 2; o is selected from 1, 2, 3, 4, 5; X is selected from CH2, NH, O. The fifth aspect of the technical solution of the present invention, in order to achieve the purpose of the present invention, the preferred compounds include but are not limited to:

[0053]

[0054]

[0055]

[0056]

[0057] The sixth aspect of the technical solution of the present invention provides a method for preparing the compounds described in the first aspect to the fifth aspect, and the technical solution adopted comprises the following steps:

[0058] According to the structure of the 3-substituent (R1, R2), the compound represented by the general formula I is synthesized by the synthesis method of Scheme 1-4;

[0059] Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a trifluoroacetyl protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 2;

[0060] Intermediate 2 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 3;

[0061] Intermediate 3 is reacted with N-formyl saccharin through coupling reaction to prepare intermediate 4;

[0062] Intermediate 4 undergoes bromination reaction with NBS to obtain intermediate 5;

[0063] Intermediate 5 was treated with potassium carbonate aqueous solution to remove the trifluoroacetyl group to obtain a compound without substitution on the N-side; a Boc protecting group was introduced to obtain intermediate 6;

[0064] Intermediate 6 is reduced to give intermediate 7;

[0065] Intermediate 7 was subjected to carbonyl insertion coupling reaction to give intermediate 8;

[0066] Intermediate 8 is treated with trifluoroacetic acid or hydrogen chloride in 1,4-dioxane to remove Boc to obtain intermediate 9;

[0067] Intermediate 9 is subjected to coupling reaction to introduce Ar to obtain a compound of formula IA;

[0068] Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a Boc protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 10;

[0069] Intermediate 10 undergoes Friedel-Crafts acylation with paraformaldehyde to prepare intermediate 11;

[0070] Intermediate 11 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 12;

[0071] Intermediate 12 undergoes Pinnick oxidation reaction to obtain intermediate 13;

[0072] Intermediate 13 undergoes esterification reaction with methyl iodide to obtain intermediate 14;

[0073] Intermediate 14 undergoes coupling reaction with potassium vinyl trifluoroborate to obtain intermediate 15;

[0074] Intermediate 15 is subjected to oxidation reaction to obtain intermediate 16;

[0075] Intermediate 16 reacts with an alkyl Grignard reagent to give intermediate 17;

[0076] Intermediate 17 is treated with trifluoroacetic acid or hydrogen chloride in 1,4-dioxane to remove Boc to obtain intermediate 18;

[0077] Intermediate 18 is subjected to coupling reaction or substitution reaction to introduce Ar to obtain a compound represented by the general formula IB;

[0078] Intermediate 15 undergoes hydrolysis to obtain intermediate 19;

[0079] Intermediate 19 is oxidized to give intermediate 20;

[0080] Intermediate 20 undergoes substitution reaction with alkyl iodide to obtain intermediate 21;

[0081] Intermediate 21 is treated with a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride to remove Boc, and Ar is introduced through a coupling reaction or a substitution reaction to obtain a compound of the general formula IB;

[0082] Intermediate 12 was reacted with triisopropylsilyl acetylene via Sonogashira coupling to prepare key intermediate 22;

[0083] The silicon protecting group of intermediate 22 was removed by tetrabutylammonium fluoride to obtain intermediate 23;

[0084] Intermediate 23 undergoes Pinnick oxidation reaction to obtain intermediate 24;

[0085] Intermediate 24 undergoes hydrolysis to obtain intermediate 25;

[0086] Intermediate 25 undergoes esterification with methyl iodide to give intermediate 26;

[0087] Intermediate 26 undergoes nucleophilic addition reaction with alkyl Grignard reagent to give intermediate 27;

[0088] Intermediate 27 is treated with trifluoroacetic acid or hydrogen chloride in 1,4-dioxane to remove Boc, and Ar is introduced through a coupling reaction to obtain a compound represented by the general formula IC;

[0089] The preferred preparation methods and conditions of the compounds represented by the general formula IA, IB, and IC are shown in Schemes 1, 2, 3, and 4;

[0090] Scheme 1

[0091]

[0092] Scheme 1.Reagents and conditions:(i)(COCF3)2O,TEA,r.t;(ii)TfCl,TEA,0℃;(iii)N-Formylsaccharin,Pd(OAc)2,DPPF,Et3SiH,MeCN;(iv)4-chloro-2-(trifluoromethyl)aniline,NBS,Pd(OAc)2,DCE:CF3COOH=5:1,60℃;(v)1)aqueousPotassium Carbonate,MeOH;2)Boc2O;(vi)NaBH4,MeOH,0℃;(vii)Co2(CO)8,Pd(OAc)2,DPPF,DMAP,1,4-dioxane,90℃,microwave;(viii)CF3COOH,NH3 H2O;(ix)Pd(OAc)2,X-Phos,Cs2CO3,1,4-dioxane,100℃.

[0093]

[0094] Scheme 2.Reagents and conditions:(i)Boc2O,TEA,r.t;(ii)(CH2O) n ,MgCl2,TEA,90℃;(iii)TfCl,TEA,0℃;(iv)NaClO2,NaH2PO4,2-Methyl-1-butene,r.t;(v)CH3I,KHCO3,60℃;(vi)Potassium ethenyltrifluoroborate,PdCl2(dppf)CH2Cl2,TEA,60℃;(vii)Sodium periodate,Potassium osmate(VI)dihydrate,-20℃-0℃;(viii)R7MgBr,THF,0℃;(xi)CF3C OOH,DCM,0℃;(x)Pd(OAc)2,X-Phos,Cs2CO3,1,4-dioxane,100℃.

[0095] Scheme 3

[0096]

[0097] Scheme 3.Reagents and conditions: (i) LiOH, MeOH / THF, 70℃; (ii) H2O2, MeCN, Triflu oroacetophenone, BuOH, buffer (K2CO3 / EDTA disodium salt=1500:1),rt; (iii) R9I, NaH, DMF; (iv) 1) CF3COOH, 0℃; 2) Pd(OAc)2, X-Phos, Cs2CO3, 1,4-dioxane, 100℃.

[0098] Scheme 4

[0099]

[0100] Scheme 4.Reagents and conditions: (i) (Triisopropylsilyl)acetylene, Pd(PPh3)2Cl2, CuI, TE A, 90℃; (ii) n-Bu4NF / THF, 0℃; (iii) NaClO2, NaH2PO4, 2-Methyl-1-butene, rt; (iv) LiO H, MeOH, 0℃; (v) MeI, KHCO3, 0℃; (vi) R8MgBr, THF; (vii) 1) CF3COOH, DCM, 0℃; 2) Pd(OAc)2, X-Phos, Cs2CO3, 1,4-dioxane, 100℃.

[0101] The definitions of Ar, R7, and R8 are the same as those of claims 1-7, and R9 is independently selected from C1, C2, C3, and C4 straight-chain or branched-chain alkyl, and halogen-substituted C1, C2, C3, and C4 straight-chain or branched-chain alkyl.

[0102] The starting materials and intermediates in the above reaction are easy to obtain, and each step of the reaction can be easily synthesized according to the reported literature or by conventional methods in organic synthesis for those skilled in the art. The compound described in general formula I can exist in the form of a solvate or an unsolvate, and different solvates may be obtained by crystallization using different solvents. The pharmaceutically acceptable salts described in general formula I include salts of different acids, such as the following inorganic or organic acids: hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, citric acid, maleic acid, tartaric acid, fumaric acid, citric acid, lactic acid. The pharmaceutically acceptable salts described in general formula I also include different alkali metal salts (lithium, sodium, potassium salts), alkaline earth metal salts (calcium, magnesium salts) and ammonium salts, and salts of organic bases that can provide physiologically acceptable cations, such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine and tris (2-hydroxyethyl) amine salts. All of these salts within the scope of the present invention can be prepared by conventional methods.

[0103] The seventh aspect of the technical solution of the present invention is to provide a pharmaceutical composition, which comprises the compound or a pharmaceutically acceptable salt thereof as described in the first to fifth aspects of the technical solution of the present invention and a commonly used pharmaceutical carrier.

[0104] The composition includes at least one compound of the present invention and a pharmaceutically acceptable carrier. The pharmaceutical composition is selected from tablets, capsules, pills, injections, sustained-release preparations, controlled-release preparations or various microparticle delivery systems. The pharmaceutical composition can be prepared according to methods well known in the art. Any dosage form suitable for human or animal use can be prepared by combining the compound of the present invention with one or more pharmaceutically acceptable solid or liquid excipients and / or adjuvants. The content of the compound of the present invention in its pharmaceutical composition is usually 0.1-95% by weight. The compound of the present invention or a pharmaceutical composition containing it can be administered in a unit dose form, and the route of administration can be enteral or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc. The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w type, w / o type and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and ointments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semi-solid dosage forms can be ointments, gels, pastes, etc.

[0105] The compounds of the present invention can be made into ordinary preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle delivery systems. These preparations are prepared according to methods well known to those skilled in the art. The auxiliary materials used to make tablets, capsules and coatings are conventional auxiliary agents, such as starch, gelatin, gum arabic, silica, polyethylene glycol, and the solvents used in liquid dosage forms are, for example, water, ethanol, propylene glycol, and vegetable oils such as corn oil, peanut oil, olive oil, etc. The preparations containing the compounds of the present invention may also contain other auxiliary agents, such as surfactants, lubricants, disintegrants, preservatives, flavoring agents, pigments, etc.

[0106] In order to prepare the compound of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc. The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.

[0107] In order to prepare the dosing unit into a capsule, the active ingredient compound of the present invention can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. The active ingredient compound of the present invention can also be first prepared into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.

[0108] To prepare the compound of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, cosolvent, pH adjuster, and osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-β-cyclodextrin, etc.; the pH adjuster can be phosphate, acetate, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support agent.

[0109] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents or other additives may be added to the pharmaceutical preparations.

[0110] In order to achieve the purpose of medication and enhance the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known administration method.

[0111] The dosage of the pharmaceutical composition of the compound of the present invention can vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form. Generally speaking, the suitable dosage range of the compound of the present invention is 0.1-1000 mg / Kg body weight per day, preferably 1-500 mg / Kg body weight. The above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment means.

[0112] The compound or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.

[0113] The eighth aspect of the technical solution of the present invention provides the use of the compounds and pharmaceutical salts thereof described in the first to fifth aspects of the present invention in the preparation of MAO-B and / or A inhibitors, in the preparation of drugs for preventing and / or treating diseases related to MAO-B and / or A, in the preparation of drugs for treating neuropsychiatric diseases, cardiovascular system diseases, metabolic diseases, and cancer treatment drugs, especially in the preparation of drugs related to diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease (HD), depression, anxiety, amyotrophic lateral sclerosis, mania, cancer, obesity, chronic obstructive pulmonary disease or pulmonary hypertension.

[0114] Beneficial technical effects:

[0115] The 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-one compounds in this patent application are MAO-B inhibitors with a completely new structure and have significant inhibitory activity against MAOB, and some compounds also have significant inhibitory activity against MAOA. DETAILED DESCRIPTION

[0116] The invention will be further described below with reference to the embodiments, but the scope of the invention is not limited thereto.

[0117] The structure of the compound is determined by nuclear magnetic resonance (NMR) or high resolution mass spectrometry (HRMS). NMR is measured using Varian mercury 400 or Varian mercury 500, the solvent is CDCl3, DMSO-d6, MD3OD, the internal standard is TMS, and the chemical shift is given in ppm. mp is the melting point given in °C, and the temperature is not corrected. Silica gel column chromatography generally uses 200-300 mesh silica gel as the carrier.

[0118] List of abbreviations:

[0119] Na2CO3: Sodium carbonate; Cs2CO3: Cesium carbonate; NaHCO3: Sodium bicarbonate; K2CO3: Potassium carbonate DMAP: 4-dimethylaminopyridine; TFA: Trifluoroacetic acid; NaCl: Sodium chloride

[0120] TEA: triethylamine; DIEA: N,N-diisopropylethylamine

[0121] DMF: N,N-dimethylformamide; THF: tetrahydrofuran; PE: petroleum ether; EA: ethyl acetate; DCM: dichloromethane; MeOH: methanol; ACN: acetonitrile

[0122] Ar: argon; min: minute; rt: room temperature; h: hour

[0123] Boc anhydride: di-tert-butyl dicarbonate; TfCl: trifluoromethanesulfonyl chloride; Ac2O: acetic anhydride; Xphos: 2-dicyclohexylphosphino-2,4,6-triisopropylbiphenyl; DPPF: 1,1'-bis(diphenylphosphino)ferrocene; NBS: N-bromosuccinimide

[0124] CDCl3: deuterated chloroform; DMSO-d6: deuterated dimethyl sulfoxide;

[0125] CD3OD: deuterated methanol

[0126] TLC: thin-layer chromatography

[0127] Embodiment 1:

[0128] Synthesis of 6-(4-chlorophenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0129]

[0130] (1) Synthesis of 2,2,2-trifluoro-1-(6-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (Intermediate 1)

[0131]

[0132] 6-Hydroxy-1,2,3,4-tetrahydroisoquinoline (1.3 g, 6.13 mmol) and trifluoroacetic anhydride (1.03 mL, 7.36 mmol) were dissolved in DMF (20 mL). Under Ar protection, TEA (1.70 mL, 12.26 mmol) was added and reacted in an ice-water bath for 0.5 h. After the reaction, the reaction solution was poured into ice water, extracted with EA (20 mL × 2), the organic phases were combined, washed with saturated NaCl solution (20 mL), dried over anhydrous MgSO4, and filtered to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA = 6%) to obtain 1.6 g of a white solid with a yield of 84.72% and a melting point of 118-120 ° C.

[0133] 1 H NMR(500MHz, CDCl3)δ(ppm)6.99(s,1H),6.78–6.70(m,1H),6.70–6.63(m,1H) ,5.75(brs,1H),4.75–4.62(m,2H),3.89–3.76(m,2H),2.89(t,J=6.0Hz,2H).

[0134] (2) Synthesis of 2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-6-yl trifluoromethanesulfonate (Intermediate 2)

[0135]

[0136] The intermediate 1 (600 mg, 2.45 mmol) was dissolved in 30 mL of ultra-dry DCM, TEA (1.02 mL, 7.34 mmol) was added, and the reaction vessel was placed in an ice-water bath. Under Ar protection, TfCl (0.60 mL, 5.63 mmol) was slowly added dropwise, and the reaction was carried out in an ice-water bath for 0.5 h. After the reaction was completed, the reaction was quenched with a saturated NH4Cl solution (10 mL), extracted with DCM (20 mL×3), the organic phases were combined, washed with saturated NaCl (20 mL), dried over anhydrous MgSO4, filtered and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=7%) to obtain 998 mg of a white solid with a yield of 92.67% and a melting point of 77-79°C.

[0137] 1H NMR(500MHz, CDCl3)δ(ppm)7.24–7.21(m,1H),7.18–7.15(m,1H),7.13–7.11(m,1H),4.82(s ,1.4H),4.77(s,0.6H),3.92(t,J=6.5Hz,0.6H),3.88(t,J=6.0Hz,1.4H),3.06–2.97(m,2H).

[0138] (3) Synthesis of 2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-carbaldehyde (Intermediate 3)

[0139]

[0140] Intermediate 2 (500 mg, 1.33 mmol) was placed in a sealed tube, and Pd(OAc)2 (15 mg, 0.066 mmol), DPPF (58 mg, 0.106 mmol), N-formyl saccharin (419 mg, 1.99 mmol) were added, and then 10 mL of ultra-dry ACN and Na2CO3 (210 mg, 1.99 mmol) were added. Under Ar protection, triethylsilane (0.32 mL, 1.99 mmol) was quickly added, and the screw cap was tightened. The reaction was heated at 80°C for 24 h. After the reaction was completed, the reaction solution was cooled to room temperature, diluted with EA (15 mL), filtered with diatomaceous earth, and the filtrate was washed with saturated NaCl (10 mL). After drying and filtration over anhydrous MgSO4, the crude product was obtained, which was purified by column chromatography (SiO2, PE / EA, EA=8%) to obtain 313 mg of a white solid with a yield of 90.01% and a melting point of 75-77°C.

[0141] 1 H NMR (500MHz, CDCl3) δ (ppm) 10.00 (s, 0.3H), 9.99 (s, 0.7H), 7.76 (d, J = 7.5Hz, 1H), 7.21 (s, 0.3H), 7.70 (s, 0.7H), 7.34 (d, J = 8.0Hz, 0.7H), 7.31 (d, J = 8.0Hz, 0.3H), 4.88 (s, 1.4H), 4.83 (s, 0.6H), 3.94 (t, J = 6.0Hz, 0.6H), 3.90 (t, J = 5.5Hz, 1.4H), 3.07–3.03 (m, 2H).

[0142] (4) Synthesis of 7-bromo-2-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-carbaldehyde (Intermediate 4)

[0143]

[0144] Intermediate 3 (600 mg × 2, 1.26 mmol) was placed in a sealed tube, and Pd(OAc)2 (53 mg × 2, 0.233 mmol), NBS (498 mg × 2, 2.80 mmol) were added, and then ultra-dry DCE 9 mL × 2 was added, and 2-amino-5-chlorotrifluorotoluene (66 μL × 2, 0.466 mmol) was added with a pipette, and trifluoroacetic acid 1.5 mL × 2 was added. Ar was filled, the screw cap was tightened, and the reaction was heated at 60°C for 12 h. After the reaction was completed, it was cooled to room temperature, quenched with saturated NaCl (20 mL), extracted with DCM (30 mL), and the organic layer was washed with saturated NaCl (20 mL), dried and filtered over anhydrous MgSO4 to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA = 6%) to obtain a total of 1.204 g of yellow solid with a yield of 76.78%.

[0145] 1 H NMR (500MHz, CDCl3) δ (ppm) 10.32 (s, 1H), 7.79 (s, 0.3H), 7.77 (s, 0.7H), 7.51 (s, 0.7H), 7.49 (s, 0.3H) ), 4.87 (s, 1.4H), 4.82 (s, 0.6H), 3.95 (t, J = 6.0Hz, 0.6H), 3.91 (t, J = 6.0Hz, 1.4H), 3.00–2.92 (m, 2H).

[0146] (5) Synthesis of tert-butyl 7-bromo-6-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 5)

[0147]

[0148] Dissolve intermediate 4 (3 g, 8.93 mmol) in methanol (60 mL), add saturated aqueous solution (60 mL) of K2CO3 (3.7 g, 26.78 mmol), protect with Ar, stir for 2 h in ice-water bath, then add Boc anhydride (4.86 g, 22.28 mmol). React for 2 h in ice-water bath, and the reaction is complete. Dilute with DCM (40 mL × 2), wash with saturated NaCl (60 mL), dry and filter with anhydrous MgSO4, concentrate to obtain crude product, column chromatography (SiO2, PE / EA, EA = 8%), obtain 2.04 g of white solid, yield 67.3%.

[0149] 1H NMR (500MHz, CDCl3) δ (ppm) 10.30 (s, 1H), 7.71 (s, 1H), 7.41 (s, 1H), 4.61 (s, 2H), 3.66 (t, J = 6.0Hz, 2H), 2.84 (t, J = 5.8Hz, 2H), 1.49 (s, 9H).

[0150] (6) Synthesis of tert-butyl 7-bromo-6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 6)

[0151]

[0152] Intermediate 5 (802 mg, 2.36 mmol) was dissolved in anhydrous MeOH (35 mL), and NaBH4 (133.7 mg, 3.54 mmol) was added. The mixture was stirred for 10 min in an ice-water bath, and the reaction was completed. Water (20 mL) was added to quench the mixture, and EA (15 mL×2) was used for extraction. The organic phases were combined, washed with saturated NaCl solution (20 mL), dried over anhydrous MgSO4, filtered, and concentrated to obtain a crude product. Column chromatography (SiO2, PE / DCM / EA, EA=12%) gave 554 mg of a white solid with a yield of 68.67% and a melting point of 105-107°C.

[0153] 1 H NMR (500MHz, CDCl3) δ (ppm) 7.41 (s, 1H), 7.31 (s, 1H), 4.48–4.46 (m, 4H), 3.53 (t, J = 6.0Hz, 2H), 2.74 (t, J = 6.0Hz, 2H), 1.42 (s, 9H).

[0154] (7) Synthesis of tert-butyl 3-carbonyl-1,5,7,8-tetrahydrofurano[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 7)

[0155]

[0156] Intermediate 6 (500 mg×6, 1.46 mmol), Pd(OAc)2 (16.4 mg×6, 0.07 mmol), Xanth-Phos (85 mg×6, 0.145 mmol), DMAP (355 mg×6, 2.92 mmol), Co2(CO)8 (120 mg×6, 0.365 mmol) were added to a microwave-sealed tube, and 8 mL of anhydrous toluene was added. The mixture was heated to 90°C in a microwave oven for 30 min. After the reaction was completed, the mixture was filtered through diatomaceous earth and concentrated to obtain a crude product. The crude product was subjected to column chromatography (SiO2, DCM / EA, EA=8-9%) to obtain 2.13 g of a white solid with a yield of 83.9% and a melting point of 115-118°C.

[0157] 1 H NMR(400MHz,DMSO-d6)δ(ppm)7.66(s,1H),7.42(s,1H),5.31(s,2H),4.56(s,2H),3. 51(t,J=6.0Hz,2H),2.88(t,J=6.0Hz,2H),1.38(s,9H); HR-MS(ESI):m / z,calcd.For C 12 H 12 O4N[(M-C4H9)+H] + 234.0761,Found:234.0775.

[0158] (8) Synthesis of 5,6,7,8-tetrahydrofuran[3,4-g]isoquinoline-3(1H)-trifluoroacetate (Intermediate 8)

[0159]

[0160] Intermediate 7 (1.43 g, 4.94 mmol) was dissolved in anhydrous DCM (30 mL), trifluoroacetic acid (7.56 mL, 98.85 mmol) was added, and the mixture was stirred for 2 h in an ice-water bath. After the reaction was completed, a large amount of anhydrous ether (20 mL) was added, and a white solid precipitated. After filtration, 600 mg of a white solid was obtained, with a yield of 65.03% and a melting point of 115-117°C. 1 H NMR(400MHz,DMSO-d6)δ(ppm)9.14(s,1H),7.80(s,1H),7.54(s,1H),5.40(s,2H),4. 38(s,2H),3.43(t,J=6.4Hz,2H),3.14(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 11 H 12 O2N[M+H] + 190.0863,Found:190.0868.

[0161] (9) Synthesis of 6-(4-chlorophenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Example 1)

[0162]

[0163] Intermediate 8 (50 mg, 0.264 mmol), p-chlorobromobenzene (101 mg, 0.528 mmol), Pd2(dba)3 (24 mg, 0.026 mmol), X-Phos (25 mg, 0.052 mmol), Cs2CO3 (172 mg, 0.528 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 5 mL was added, Ar was protected, and the reaction was heated under reflux for 5 h. After the reaction was completed, the reaction solution was cooled to room temperature. Filtered through diatomaceous earth, the filtrate was diluted with EA (20 mL), washed with saturated NaCl (10 mL), dried and filtered with anhydrous MgSO4, and concentrated to obtain a crude product. Purified by column chromatography (SiO2, PE / EA, EA=20%), 30 mg of a light yellow solid was obtained, with a yield of 37.87%, and a melting point of 160-162°C.

[0164] 1 H NMR (500MHz, DMSO-d6) δ (ppm) 7.75 (s, 1H), 7.47 (s, 1H), 7.25 (d, J = 8.5Hz, 2H), 7.01 (d, J = 9.0Hz, 2H) ,5.36(s,2H),4.52(s,2H),3.57(t,J=6.0Hz,2H),3.05(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 17 H 15 O2NCl[M+H] + 300.0786,Found:300.0787.

[0165] Embodiment 2:

[0166] Synthesis of 6-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0167]

[0168] Intermediate 8 (100 mg, 0.528 mmol), Pd2(dba)3 (48 mg, 0.052 mmol), X-Phos (50 mg, 0.105 mmol), Cs2CO3 (344 mg, 1.06 mmol) were added to a 25 mL two-necked round-bottom flask, and 1,4-Dioxane 6.0 mL was added. Then p-bromotrifluoromethylbenzene (148 μL, 1.06 mmol) was added, Ar was protected, and the mixture was heated under reflux in an oil bath for 3.5 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, diluted with DCM (20 mL), washed with saturated NaCl solution (10 mL), dried over anhydrous MgSO4, and filtered to obtain a crude product. Column chromatography (SiO2, PE / EA, EA=20%) was performed to obtain 134 mg of a yellow-brown solid. The solid was washed with anhydrous ether to obtain 81 mg of an off-white solid with a yield of 45.9% and a melting point of 158-160°C.

[0169] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.79 (s, 1H), 7.53 (d, J = 8.8Hz, 2H), 7.51 (s, 1H), 7.10 (d ,J=8.8Hz,2H),5.38(s,2H),4.66(s,2H),3.67(t,J=6.0Hz,2H),3.09(t,J=6.0Hz,2H); 13 C NMR (150MHz, DMSO-d6) δ (ppm) 170.51, 151.78, 145.57, 142.40, 135.60, 126.24 (q, J = 3.75Hz), 125.10 (q, J = 268.5Hz ),122.94,122.90,122.35,116.84(q,J=31.8Hz),113.00,69.58,48.21,44.24,28.61; HR-MS(ESI):m / z,calcd.For C 18 H 15 O2NF3[M+H] + 334.1049,Found:334.1046.

[0170] Embodiment 3:

[0171] Synthesis of 6-(3-chlorophenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0172]

[0173] Intermediate 8 (100 mg, 0.528 mmol), Pd2(dba)3 (24 mg, 0.026 mmol), X-Phos (25 mg, 0.052 mmol), Cs2CO3 (344 mg, 1.06 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-Dioxane 6.0 mL and m-chlorobromobenzene (144 μL, 1.06 mmol) were added, Ar was protected, and the mixture was heated under reflux in an oil bath for 3.5 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, the filtrate was diluted with DCM (20 mL), washed with saturated NaCl solution (10 mL), dried over anhydrous MgSO4, and filtered to obtain a crude product. The crude product was filtered through a column chromatography (SiO2, PE / DCM / EA, DCM=95%-97%), and concentrated to obtain a solid. The solid was washed with anhydrous ether to obtain 40 mg of an off-white solid with a yield of 25.25% and a melting point of 157-159°C.

[0174] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.77 (s, 1H), 7.48 (s, 1H), 7.23 (t, J = 8.4Hz, 1H), 7.01 (t, J = 2.4Hz, 1H), 6.95 (dd, J1 = 8.4Hz, J2 = 2.4Hz, 1H) ,6.75(dd,J1=8.0Hz,J2=2.0Hz,1H),5.36(s,2H),4.56(s,2H),3.59(t,J=6.0Hz,2H),3.06(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 17 H 15 O2NCl[M+H] + 300.0786,Found:300.0786.

[0175] Embodiment 4:

[0176] Synthesis of 6-(3-chloro-4-methylphenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0177]

[0178] Intermediate 8 (86 mg, 0.454 mmol), Pd(OAc)2 (5 mg, 0.022 mmol), X-Phos (22 mg, 0.045 mmol), Cs2CO3 (222 mg, 0.687 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and 4-bromo-2-chlorotoluene (73 μL, 0.545 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 3 h. After the reaction was completed, the mixture was filtered on diatomaceous earth, the filtrate was diluted with DCM (10 mL×2), washed with saturated NaCl solution (5 mL), dried over anhydrous MgSO4, and filtered to obtain a crude product. The product was concentrated to obtain a solid, and washed with anhydrous ether to obtain 35 mg of an off-white solid with a yield of 47.7% and a melting point of 148-150°C.

[0179] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.71 (s, 1H), 7.41 (s, 1H), 7.13 (d, J = 8.0Hz, 1H), 6.97 (d, J = 2.8Hz, 1H), 6.85 (dd, J1=8.8Hz, J2=2.4Hz,1H),5.31(s,2H),4.45(s,2H),3.50(t,J=6.0Hz,2H),2.99(t,J=6.0Hz,2H),2.16(s,3H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)170.55,149.05,145.27,142.06,135.73,133.82,131.39,124.04,122. 96,122.80,122.52,114.53,113.58,69.55,49.36,45.27,28.59,18.44; HR-MS(ESI):m / z,calcd.ForC 18 H 17 O2NCl[M+H] + 314.0942,Found:314.0943.

[0180] Embodiment 5:

[0181] Synthesis of 6-(3-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0182]

[0183] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.052 mmol), Cs2CO3 (344 mg, 1.06 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-Dioxane 6.0 mL and m-trifluoromethyl bromobenzene (147 μL, 1.06 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 2.5 h. After the reaction was completed, the filtrate was filtered on diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was concentrated to obtain a yellow solid by column chromatography (SiO2, PE / EA, EA=20%), and washed with anhydrous ether to obtain 76 mg of a light yellow solid with a yield of 43.14% and a melting point of 157-159°C.

[0184] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.80 (s, 1H), 7.50 (s, 1H), 7.44 (t, J = 8.0Hz, 1H), 7.27 (dd, J1 = 8.4Hz, J2 = 2.4Hz, 1 H),7.23(s,1H),7.04(d,J=7.6Hz,1H),5.37(s,2H),4.62(s,2H),3.65(t,J=6.0Hz,2H),3.09(t,J=5.6Hz,2H); 13 C NMR (150MHz, DMSO-d6) δ (ppm) 170.54, 149.81, 145.44, 142.22, 135.61, 130.02, 129.98 (q, J = 30.8Hz), 124.50 (q, J = 270.9Hz), 122 .98,122.90,122.43,117.67,113.61(q,J=4.2Hz),109.81(q,J=3.9Hz),69.57,48.74,44.77,28.74; HR-MS(ESI):m / z,calcd.For C 18 H 15 O2NF3[M+H] + 334.1049,Found:334.1049.

[0185] Embodiment 6:

[0186] Synthesis of 6-(p-Tolyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0187]

[0188] Intermediate 8 (100 mg, 0.528 mmol), p-bromotoluene (180 mg, 1.06 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.052 mmol) and Cs2CO3 (344 mg, 1.06 mmol) were added to a 25 mL two-necked round-bottom flask, and 6.0 mL of 1,4-dioxane was added. Ar protection, oil bath heating reflux, reaction for 2 h. After the reaction was completed, diatomaceous earth was filtered, and the filtrate was concentrated to obtain a crude product, column chromatography (SiO2, PE / EA, EA=15%-17%), concentrated to obtain a solid, washed with anhydrous ether, and obtained 59 mg of a bright yellow solid, with a yield of 39.96%, and a melting point of 147-149°C.

[0189] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.74 (s, 1H), 7.45 (s, 1H), 7.05 (d, J = 8.0Hz, 2H), 6.92 (d, J = 8.8 Hz,2H),5.36(s,2H),4.46(s,2H),3.52(t,J=5.6Hz,2H),3.04(t,J=6.0Hz,2H),2.20(s,3H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)170.57,147.71,145.13,142.08,136.06,129.47,127.09,122. 94,122.72,122.58,115.26,69.53,50.19,45.94,28.83,20.00; HR-MS(ESI):m / z,calcd.For C 18 H 18 O2N[M+H] + 280.1332,Found:280.1330.

[0190] Embodiment 7:

[0191] Synthesis of 6-(3,4-difluorophenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0192]

[0193] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.052 mmol) and Cs2CO3 (344 mg, 1.06 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and 3,4-difluorobromobenzene (120 μL, 1.06 mmol) were added, Ar was protected, and the mixture was heated under reflux in an oil bath for 3 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product. The crude product was concentrated to obtain a solid by column chromatography (SiO2, PE / EA, EA=20%), and washed with anhydrous ether to obtain 60 mg of a light yellow solid with a yield of 37.8% and a melting point of 185-187°C.

[0194] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.74 (s, 1H), 7.48 (s, 1H), 7.30–7.23 (m, 1H), 7.05 (ddd, J1=14.4Hz, J2=7.2Hz, J2=3.2Hz, 1H ),6.80–6.76(m,1H),5.37(s,2H),4.51(s,2H),3.56(t,J=6.0Hz,2H),3.05(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 17 H 14 O2NF2[M+H] + 302.0987,Found:302.0985.

[0195] Embodiment 8:

[0196] Synthesis of 6-(m-Tolyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0197]

[0198] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.052 mmol) and Cs2CO3 (344 mg, 1.06 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-Dioxane 6.0 mL and m-bromotoluene (96 μL, 0.792 mmol) were added, Ar was protected, and the mixture was heated under reflux in an oil bath for 3.5 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, the filtrate was concentrated, and column chromatography (SiO2, PE / EA, EA=17%) was performed to obtain a solid, which was washed with anhydrous ether to obtain 63 mg of a bright yellow solid with a yield of 42% and a melting point of 158-160°C.

[0199] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.75 (s, 1H), 7.46 (s, 1H), 7.11 (t, J = 8.0Hz, 1H), 6.84 (s, 1H), 6.80 (dd, J1 = 8.4Hz, J2 = 2 .4Hz,1H),6.58(d,J=7.6Hz,1H),5.36(s,2H),4.50(s,2H),3.55(t,J=5.6Hz,2H),3.05(t,J=6.0Hz,2H),2.26(s,3H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)170.57,149.77,145.18,142.20,138.08,136.06,128.86,122.91,122. 76,122.51,119.04,115.41,112.01,69.53,49.65,45.44,28.79,21.46; HR-MS(ESI):m / z,calcd.For C 18 H 18 O2N[M+H] + 280.1332,Found:280.1327.

[0200] Embodiment 9:

[0201] Synthesis of 6-(phenyl[d][1,3]methylenedioxy-5-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0202]

[0203] Intermediate 8 (90 mg, 0.475 mmol), Pd(OAc)2 (5 mg, 0.023 mmol), X-Phos (23 mg, 0.047 mmol), Cs2CO3 (233 mg, 0.72 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and 1-bromo-3,4-(methylenedioxy)benzene (115 μL, 1.06 mmol) were added, Ar was protected, the oil bath was heated to reflux, and the reaction was carried out for 2.0 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, the filtrate was concentrated, and the anhydrous ether was used for multiple pulping and washing to obtain 100 mg of a light yellow solid with a yield of 40% and a melting point of 195-197°C.

[0204] 1H NMR(400MHz,DMSO-d6)δ(ppm)7.71(s,1H),7.44(s,1H),6.83–6.74(m,2H),6.43 (dd, J1=8.4Hz, J2=2.4Hz,1H),5.91(s,2H),5.35(s,2H),4.39(s,2H),3.45(t,J = 6.0Hz, 2H), 3.03 (t, J = 6.0Hz, 2H); 13 C NMR (150 MHz, DMSO-d6) δ (ppm)170.57,147.96,145.97,145.11,141.92,140.22,136.00,122.88,122.70,122.59, 108.15,107.62,100.51,98.87,69.53,51.25,47.03,28.82; HR-MS(ESI):m / z,calcd.For C 18 H 16 O4N[M+H] + 310.1074,Found:310.1074.

[0205] Embodiment 10:

[0206] Synthesis of 6-(3-fluorophenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0207]

[0208] Intermediate 8 (90 mg, 0.475 mmol), Pd(OAc)2 (5 mg, 0.023 mmol), X-Phos (23 mg, 0.047 mmol) and Cs2CO3 (233 mg, 0.72 mmol) were placed in a 25 mL two-necked round-bottom flask, and 6.0 mL of 1,4-dioxane was added. Then o-fluorobromobenzene (105 μL, 0.951 mmol) was added, Ar was protected, and the mixture was heated under reflux in an oil bath for 4.0 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified and concentrated by column chromatography (SiO2, PE / EA EA=20%) to obtain a white solid, which was washed with anhydrous ether to obtain 10 mg of a white solid with a yield of 7.8% and a melting point of 174-176°C.

[0209] 1H NMR(400MHz,CD3OD)δ(ppm)7.69(s,1H),7.42(s,1H),7.18–6.95(m,4H),5.35(s,2H), 4.40(s,2H),3.47(t,J=5.6Hz,2H),3.14(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 17 H 15 O2NF[M+H] + 284.1081,Found:284.1089.

[0210] Embodiment 11:

[0211] Synthesis of 6-(3,4,5-trifluorophenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0212]

[0213] Intermediate 8 (90 mg, 0.475 mmol), Pd(OAc)2 (5 mg, 0.023 mmol), X-Phos (23 mg, 0.047 mmol) and Cs2CO3 (233 mg, 0.72 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-Dioxane 6.0 mL and 3,4,5-trifluorobromobenzene (114 μL, 0.951 mmol) were added, Ar was protected, and the mixture was heated under reflux in an oil bath for 5.0 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by washing with anhydrous ether several times to obtain 15 mg of a white solid with a yield of 10.8% and a melting point of >250°C.

[0214] 1 H NMR(400MHz,DMSO-d6)δ(ppm)7.73(s,1H),7.49(s,1H),6.94–6.81(m,2H),5.37(s,2H) ,4.54(s,2H),3.56(t,J=6.0Hz,2H),3.05(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 17 H 13 O2NF3[M+H] + 320.0893,Found:320.0898.

[0215] Embodiment 12:

[0216] Synthesis of 6-(3-bromophenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0217]

[0218] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.053 mmol), Cs2CO3 (258.29 mg, 0.79 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-Dioxane 6.0 mL and m-dibromobenzene (194 μL, 1.06 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 6.0 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=27%, DCM / EA, EA=2%) and washed with anhydrous ether to obtain 15 mg of a white solid with a yield of 8.5% and a melting point of 140-142°C.

[0219] 1 H NMR (400MHz, CD3OD) δ (ppm) 7.76 (s, 1H), 7.43 (s, 1H), 7.20–7.10 (m, 2H), 6.98 (ddd, J1 = 8.4Hz, J2 = 2.4Hz, J3 = 0.8Hz, 1H), 6.91 (ddd, J1 =7.6Hz, J2=1.6Hz, J3=0.8Hz,1H),5.35(s,2H),4.53(s,2H),3.61(t,J=6.0Hz,2H),3.13(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 17 H 15 O2NBr[M+H] + 344.0281,Found:344.0298.

[0220] Embodiment 13:

[0221] Synthesis of 6-(5-fluoropyrimidin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0222]

[0223] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.053 mmol) and Cs2CO3 (258.29 mg, 0.79 mmol) were placed in a sealed tube, 1,4-Dioxane 6.0 mL and 2-bromo-5-fluoropyrimidine (187 μL, 1.06 mmol) were added, Ar was protected, the tube was sealed at 100°C, and the reaction was carried out for 16 hours. After the reaction was completed, the product was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, DCM / EA, EA=8%) to obtain 30 mg of a yellow solid with a yield of 19.90% and a melting point of 210-212°C. 1 H NMR (400MHz, DMSO-d6) δ (ppm) 8.51 (s, 2H), 7.78 (s, 1H), 7.50 (s, 1H), 5.37 (s, 2H), 4.94 (s, 2H), 3.95 (t, J = 6.0Hz, 2H), 3.04 (t, J = 6.0Hz, 2H); 13 C NMR (150MHz, DMSO-d6) δ (ppm) 170.48, 158.10, 151.54 (d, J = 244.05Hz), 145.57 (d, J = 21.5Hz), 145.4 1,142.46,135.48,123.03,122.88,122.62,69.54,46.15,41.41,28.82; HR-MS(ESI):m / z,calcd.For C 15 H 13 O2N3F[M+H] + 286.0986,Found:286.0982.

[0224] Embodiment 14:

[0225] Synthesis of 6-(5-fluoropyridin-3-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0226]

[0227] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.053 mmol) and Cs2CO3 (258.29 mg, 0.79 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 5-bromo-3-fluoropyridine (186 μL, 1.06 mmol) were added, Ar was protected, the tube was sealed and reacted at 100°C for 20 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 2%-9%) to obtain 123 mg of a white solid with a yield of 81.86% and a melting point of 214-216°C.

[0228] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 8.20 (t, J = 2.4Hz, 1H), 7.86 (d, J = 2.4Hz, 1H), 7.72 (s, 1H), 7.46 (s, 1H), 7.24 (dt, J1 = 12.8 Hz,J2=2.4Hz,1H),5.33(s,2H),4.59(s,2H),3.61(t,J=6.0Hz,2H),3.04(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 16 H 14 O2N2F[M+H] + 285.1034,Found:285.1040.

[0229] Embodiment 15:

[0230] Synthesis of 6-(6-methoxypyridin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0231]

[0232] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.053 mmol) and Cs2CO3 (258.29 mg, 0.79 mmol) were placed in a sealed tube, 1,4-Dioxane 6.0 mL and 2-bromo-6-methoxypyridine (129.1 μL, 1.06 mmol) were added, Ar was protected, and the tube was sealed and reacted at 85°C for 20 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 2%-8%) to obtain 112 mg of a yellow solid with a yield of 71.52% and a melting point of 178-180°C.

[0233] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.77 (s, 1H), 7.50–7.44 (m, 2H), 6.36 (d, J=8.0Hz, 1H), 6.04 (d, J= 7.6Hz,1H),5.37(s,2H),4.79(s,2H),3.83(s,3H),3.82(t,J=6.4Hz,2H),3.05(t,J=6.0Hz,2H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)170.54,162.41,156.93,145.35,142.70,140.41,135.96,122.89 ,122.79,122.51,98.03,97.11,69.56,52.49,46.47,41.76,28.65; HR-MS(ESI):m / z,calcd.For C 17 H 17 O3N2[M+H] + 297.1234,Found:297.1238.

[0234] Embodiment 16:

[0235] Synthesis of 6-(2-bromopyridin-4-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0236]

[0237] Intermediate 8 (89 mg, 0.470 mmol) and Cs2CO3 (306 mg, 0.94 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 2-bromo-4-fluoropyridine (73 μL, 0.705 mmol) were added, Ar was protected, and the tube was sealed and reacted at 100°C for 20 h. TLC showed that a large amount of raw materials remained, and cesium carbonate 1 eq (153 mg, 0.47 mmol) and DMF 5 mL were added, and the reaction was continued for 10 h. After the reaction was completed, the temperature was cooled to room temperature, filtered with diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, DCM / MeOH, MeOH=3%-4%), concentrated to obtain a solid, and washed with anhydrous ether to obtain 55 mg of an off-white solid with a yield of 33.87% and a melting point of >250°C.

[0238] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.90 (d, J = 6.0Hz, 1H), 7.75 (s, 1H), 7.49 (s, 1H), 6.98 (d, J = 2.4Hz, 1H), 6.86 (dd, J1 = 6.4 Hz,J2=2.4Hz,1H),5.34(s,2H),4.63(s,2H),3.59(t,J=6.0Hz,2H),3.04(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 16 H 14 O2N2Br[M+H] + 345.0233,Found:345.0240.

[0239] Embodiment 17:

[0240] Synthesis of 6-(6-methylpyridin-3-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0241]

[0242] Intermediate 8 (95 mg, 0.502 mmol), Pd(OAc)2 (9 mg, 0.040 mmol), X-Phos (36 mg, 0.075 mmol) and Cs2CO3 (246 mg, 0.75 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 5-bromo-2-methylpyridine (173 μL, 1.00 mmol) were added, Ar was protected, the tube was sealed at 85°C, and the reaction was carried out for 20 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 8%-10%) and concentrated to obtain a yellow solid, which was washed with anhydrous ether to obtain 60 mg of a yellowish solid with a yield of 42.63% and a melting point of >250°C.

[0243] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 8.20 (d, J = 3.2Hz, 1H), 7.71 (s, 1H), 7.42 (s, 1H), 7.30 (dd, J1 = 8.4Hz, J2 = 3.2Hz, 1 H),7.07(d,J=8.4Hz,1H),5.32(s,2H),4.48(s,2H),3.53(t,J=6.0Hz,2H),3.01(t,J=6.0Hz,2H),2.31(s,3H); 13C NMR(150MHz,DMSO-d6)δ(ppm)170.54,147.02,145.26,143.46,141.88,136.26,135.59,122.98, 122.82,122.80,122.62,122.42,69.55,49.40,45.23,28.42,22.78; HR-MS(ESI):m / z,calcd.For C 17 H 17 O2N2[M+H] + 281.1285,Found:281.1272.

[0244] Embodiment 18:

[0245] Synthesis of 6-(5-methylpyrimidin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0246]

[0247] Intermediate 8 (95 mg, 0.502 mmol), Pd(OAc)2 (9 mg, 0.040 mmol), X-Phos (36 mg, 0.075 mmol), Cs2CO3 (246 mg, 0.75 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 2-bromo-5-methylpyrimidine (174 μL, 1.00 mmol) were added, Ar was protected, and the tube was sealed and reacted at 85°C for 20 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, the filtrate was concentrated, and the anhydrous ether was used for multiple pulping and washing to obtain 45 mg of a white solid with a yield of 31.86% and a melting point of >250°C.

[0248] 1 H NMR(400MHz,DMSO-d6)δ(ppm)8.42(s,2H),7.70(s,1H),7.44(s,1H),5.32(s ,2H),4.54(s,2H),3.58(t,J=6.0Hz,2H),3.03(t,J=6.0Hz,2H),2.44(s,3H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)171.00,156.85,145.90,143.37,142.23,141.25,135.61,1 23.47,123.38,123.16,70.08,48.83,44.69,28.69,24.84; HR-MS(ESI):m / z,calcd.ForC 16 H 16 O2N3[M+H]+ 282.1237,Found:282.1224.

[0249] Embodiment 19:

[0250] Synthesis of 6-(4-fluoropyridin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0251]

[0252] Intermediate 8 (100 mg, 0.528 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.053 mmol) and Cs2CO3 (258.29 mg, 0.79 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-Dioxane 6.0 mL and 2-bromo-4-fluoropyridine (109 μL, 1.06 mmol) were added, Ar was protected, and the mixture was heated under reflux in an oil bath for 6 h. After the reaction was completed, the mixture was filtered on diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, DCM / EA, EA=9%) and concentrated to obtain a white solid, which was washed with anhydrous ether to obtain 40 mg of a white solid with a yield of 26.62% and a melting point of 168-170°C.

[0253] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 8.11 (dd, J1=10.0Hz, J2=5.6Hz, 1H), 7.71 (s, 1H), 7.46 (s, 1H), 6.67 (dd, J1=13.2Hz, J2=2.0Hz, 1H), 6.50 (dd d, J1=8.8Hz, J2=5.6Hz, J3=2.0Hz, 1H), 5.33 (s, 2H), 4.78 (s, 2H), 3.78 (t, J=6.0Hz, 2H), 3.01 (t, J=6.0Hz, 2H); HR-MS (ESI): m / z, calcd.For C 16 H 14 O2N2F[M+H] + 285.1034,Found:285.1039.

[0254] Embodiment 20:

[0255] Synthesis of 1-(Methoxymethyl)-6-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0256]

[0257] (1) Synthesis of tert-butyl 6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 9)

[0258]

[0259] 1,2,3,4-Tetrahydroisoquinolin-6-ol (298 mg, 2 mmol) and Boc anhydride (436 mg, 2 mmol) were dissolved in anhydrous MeOH (3 mL). TEA (0.56 mL, 4 mmol) was added under Ar protection and reacted at room temperature for 1 h. After the reaction, the solvent was dried and EA (20 mL) was added. The organic phase was washed with water (10 mL), 1N HCl (10 mL) and saturated NaHCO3 solution (10 mL), dried over anhydrous MgSO4, filtered, and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA = 15%) to obtain 332 mg of a white solid with a yield of 66.5% and a melting point of 115-117°C.

[0260] 1 H NMR (500MHz, CDCl3) δ (ppm) 6.96 (d, J = 8.5 Hz, 1H), 6.67 ( d, J = 8.5 Hz, 1H), 6.62 ( s,1H),4.49(s,2H),3.61(t,J=6.0Hz,2H),2.77(t,J=6.0Hz,2H),1.49(s,9H).

[0261] (2) Synthesis of tert-butyl 7-formyl-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate and tert-butyl 5-formyl-6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 10)

[0262]

[0263] Intermediate 9 (290 mg, 1.16 mmol) was dissolved in 10 mL of ultra-dry ACN and (CH2O) was added. n (209 mg, 6.98 mmol), MgCl2 (166 mg, 1.74 mmol), and then TEA (0.6 mL, 4.3 mmol) was added dropwise. The reaction was heated under reflux for 3 h. The reaction solution changed from white turbidity to light yellow turbidity. After the reaction was completed, diatomaceous earth was filtered, the filtrate was concentrated, EA (20 mL) was added, the organic phase was washed with water (10 mL), saturated NH4Cl solution (10 mL), saturated NaHCO3 (10 mL) and saturated NaCl (10 mL), dried and filtered over anhydrous MgSO4, and concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / EA, EA=6%) to obtain 238 mg of a light yellow solid with a yield of 73.78%.

[0264] Minor product: 1 H NMR (400MHz, CDCl3) δ (ppm) 11.96 (s, 1H), 10.31 (s, 1H), 7.24 (d, J = 8.6Hz, 1H), 6.85 (d ,J=8.6Hz,1H),4.50(s,2H),3.70(t,J=6.0Hz,2H),3.15(t,J=6.0Hz,2H),1.50(s,9H);

[0265] Major products: 1 H NMR (400MHz, CDCl3) δ (ppm) 10.84 (s, 1H), 9.83 (s, 1H), 7.30 (s, 1H), 6.78 (s, 1H), 4.55 (s, 2H), 3.63 (t, J = 6.0Hz, 2H), 2.86 (t, J = 6.0Hz, 2H), 1.50 (s, 9H).

[0266] (3) Synthesis of tert-butyl 7-formyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate and tert-butyl 5-formyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 11)

[0267]

[0268] After the intermediate 10 (1 g, 3.61 mmol) and TEA (1.0 mL, 7.21 mmol) were dissolved in anhydrous DCM (18 mL), the reaction vessel was placed in an ice-water bath. TfCl (0.6 mL, 5.41 mmol) was slowly added under Ar protection, and the reaction was carried out in an ice-water bath for 1 h. After the reaction was completed, the reaction was quenched with a saturated NaHCO3 solution (10 mL), and the reaction solution was extracted with DCM (10 mL×3) three times. The organic phases were combined, washed with saturated NaCl (30 mL), dried and filtered over anhydrous MgSO4, and the filtrate was concentrated to obtain a crude product, which was purified by column chromatography (SiO2, PE / DCM / EA, PE=80%) to obtain 947 mg of the product as a yellow oil with a yield of 64.15%.

[0269] Minor product: 1 H NMR (400MHz, CDCl3) δ (ppm) 10.48 (s, 1H), 7.42 (d, J = 8.4Hz, 1H), 7.24 (d, J = 8.4 Hz,1H),4.63(s,2H),3.64(t,J=6.0Hz,2H),3.25(t,J=6.0Hz,2H),1.49(s,9H).

[0270] Major products: 1 H NMR (400MHz, CDCl3) δ (ppm) 10.21 (s, 1H), 7.73 (s, 1H), 7.18 (s, 1H), 4.65 (s, 2H), 3.69 (t, J = 6.0Hz, 2H), 2.94 (t, J = 6.0Hz, 2H), 1.49 (s, 9H).

[0271] (4) Synthesis of 2-(tert-butoxycarbonyl)-6-(((trifluoromethyl)sulfonyl)oxy)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (Intermediate 12)

[0272]

[0273] NaH2PO4 (1.05 g, 8.72 mmol) was dissolved in water (20 mL), and NaClO2 (1.31 g / 80%, 11.63 mmol) was added to the solution, and stirred at room temperature for 10 min. Meanwhile, in another round-bottom flask, intermediate 11 (1.19 g, 2.91 mmol) was dissolved in a mixed solvent of BuOH / THF (18 mL / 4 mL), and 2-methyl-2-butene (12 mL, 101.74 mmol) was added at room temperature, and then the aqueous phase was added dropwise to the organic phase, and the temperature was raised to 45°C and the reaction was continued with stirring for 3 h. After the reaction, dilute with EA (40 mL), wash the organic phase with saturated NaCl (10 mL), dry, filter and concentrate to obtain 1.18 g of crude product as a white solid with a yield of 95.43%. The crude product was recrystallized with EtOH at 80°C to obtain 590 mg of a white solid with a yield of 40% and a melting point of 95-97°C.

[0274] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.84 (s, 1H), 7.30 (s, 1H), 4.54 (s, 2H), 3.52 (t, J = 5.8Hz, 2H), 2.84 (t, J = 5.9Hz, 2H), 1.38 (s, 9H).

[0275] (5) Synthesis of 2-(tert-butyl)7-methyl 6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (Intermediate 13)

[0276]

[0277] Intermediate 12 (200 mg, 470.71 μmol) was dissolved in DMF (7 mL), KHCO3 (57 mg, 564.21 μmol) was added, and the mixture was stirred at room temperature for 5 min under Ar protection. Then MeI (0.1 mL, 1.41 mmol) was added and the mixture was heated at 40 °C for 0.5 h. After the reaction was completed, the mixture was filtered, and the filtrate was diluted with EA (20 mL). The organic phase was washed with saturated NaCl (10 mL), dried, filtered, and concentrated to obtain the crude product. Column chromatography (SiO 2, , PE / EA, EA=12%) to give 159 mg of a light yellow solid with a yield of 76.96% and a melting point of 172-174°C. 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.92 (s, 1H), 7.39 (s, 1H), 4.61 (s, 2H), 3.88 (s, 3H), 3.58 (t, J = 6.0Hz, 2H), 2.90 (t, J = 6.0Hz, 2H), 1.45 (s, 9H).

[0278] (6) Synthesis of 2-(tert-butyl)-7-methyl-6-vinyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (Intermediate 14)

[0279]

[0280] Intermediate 13 (6.39 g, 14.54 mmol) and potassium vinyl trifluoroborate (2.92 g, 21.81 mmol) were dissolved in methanol (50 mL), and then bistriphenylphosphine palladium dichloromethane complex (235 mg, 290.85 mmol) and TEA (3.64 mL, 26.18 mmol) were added, and heated in an oil bath at 60°C for 3 h under Ar protection. After the reaction was completed, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated and purified by column chromatography (SiO2, PE / EA, EA=9%) to obtain 4.71 g of a white solid with a yield of 99% and a melting point of 56-58°C.

[0281] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.62 (s, 1H), 7.50 (s, 1H), 7.31 (dd, J1 = 17.6Hz, J2 = 11.2Hz, 1H), 5.73 (dd, J1 = 17.6Hz, J2 = 1.6Hz, 1H), 5.32 (dd, J1 = 11.2Hz, J2 = 1.2Hz, 1H), 4.53 (s, 2H), 3.82 (s, 3H), 3.56 (t, J = 5.9Hz, 2H), 2.84 (t, J = 6.0Hz, 2H), 1.43 (s, 9H).

[0282] (7) Synthesis of 2-(tert-butoxycarbonyl)-6-vinyl-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid (Intermediate 15)

[0283]

[0284] Intermediate 14 (3.71 g, 11.67 mmol) was dissolved in a mixed solvent of MeOH (20 mL) and THF (10 mL), and a solution of LiOH (840 mg, 35.07 mmol) in water (10 mL) was added dropwise at room temperature, and the mixture was protected with Ar and reacted at 70°C for 3 h. After the reaction, the solvent was dried, water (10 mL) was added, and the mixture was extracted with ether (10 mL×2). The pH value of the aqueous phase was adjusted to 3-4 with 2N HCl, and a white solid was precipitated. The mixture was filtered and the filter cake was washed with water to obtain 3.3 g of a white solid with a yield of 93.67% and a melting point of 145-147°C.

[0285] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 12.88 (s, 1H), 7.62 (s, 1H), 7.47 (s, 1H), 7.41 (dd, J1 = 17.6Hz, J2 = 11.2Hz, 1H), 5.71 (dd, J1 = 17.6 Hz,J2=1.6Hz,1H),5.29(dd,J1=11.2Hz,J2=1.6Hz,1H),4.52(s,2H),3.56(t,J=6.0Hz,2H),2.83(t,J=6.0Hz,2H),1.43(s,9H).

[0286] (8) Synthesis of tert-butyl 1-(hydroxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 16)

[0287]

[0288] The intermediate 15 (3.32 g, 10.94 mmol) was dissolved in BuOH (30 mL), and 2,2,2-trifluoroacetophenone (762 mg, 4.38 mmol) was added, followed by the addition of 20 mL of buffer (K2CO3 / EDTA disodium salt = 1500:1) solution and ACN (7.2 mL, 175.11 mmol), and finally 30% H2O2 (17.89 mL, 175.11 mmol) was added and stirred at room temperature for 6 h. After the reaction was completed, 2N HCl (30 mL) solution was added to quench the reaction, the reaction solution was extracted with EA (50 mL), the organic phase was washed with saturated NaCl (40 mL), dried over anhydrous MgSO4, filtered and concentrated. Purification by column chromatography (SiO2, DCM / MeOH, MeOH = 3-4%) gave 2.5 g of a white solid with a yield of 71.66% and a melting point of 154-155°C.

[0289] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.68 (s, 1H), 7.48 (s, 1H), 5.55 (t, J = 4.4Hz, 1H), 4.61 (s, 2H), 3.90 (dd, J1 = 12.4Hz, J2 = 4.0Hz, 1H ), 3.73 (dd, J1 = 12.4Hz, J2 = 4.8Hz, 1H), 3.56 (t, J = 6.0Hz, 2H), 2.93 (t, J = 6.0Hz, 2H), 1.43 (s, 9H); HR-MS (ESI): m / z, calcd.ForC 13 H 14 O5N[(M-C4H9)+H] + 264.0866,Found:264.0879.

[0290] (9) Synthesis of tert-butyl 1-(methoxymethyl)-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 17)

[0291]

[0292] Intermediate 16 (2.5 g, 7.83 mmol) was dissolved in DMF (20 mL), the reaction flask was placed in an ice-water bath, Ar was protected, NaH (469.65 mg, 11.74 mmol) in DMF solution (15 mL) was added dropwise, and then MeI (2.2 g, 15.66 mmol) was added. After 1 h, the temperature was raised to room temperature and reacted for 1 h. After the reaction was completed, water (20 mL) was added to quench, the reaction solution was extracted with EA (10 mL×3), the organic phases were combined, washed with water (20 mL), washed with saturated NaCl (20 mL), dried over anhydrous MgSO4, and purified by column chromatography (SiO2, P / E EA=9%) to obtain 1.68 g of a white solid with a yield of 64.3% and a melting point of 100-102°C.

[0293] 1 H NMR (400MHz, CD3OD) δ (ppm) 7.62 (s, 1H), 7.42 (s, 1H), 5.59 (t, J = 4.8Hz, 1H), 4.64 (s, 2H), 3.85 (dd, J1 = 10.8Hz, J2 = 3.2Hz, 1H), 3.70 (dd, J1=11.2Hz, J2=5.2Hz, 1H), 3.63 (t, J=6.0Hz, 2H), 3.33 (s, 3H), 2.97 (t, J=6.0Hz, 2H), 1.47 (s, 9H); HR-MS (ESI): m / z, calcd.For C 14 H 16 O5N[(M-C4H9)+H] + 278.1023,Found:278.1041.

[0294] (10) Synthesis of 1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Intermediate 18)

[0295]

[0296] Intermediate 17 (1.68 g, 5.04 mmol) was dissolved in anhydrous DCM (40 mL), trifluoroacetic acid (7.72 mL, 100.78 mmol) was added in an ice-water bath, and stirred in an ice-water bath for 1 h. The mixture was concentrated, and the excess trifluoroacetic acid was removed by spin drying with a small amount of DCM several times. A large amount of ammonia was then added to free the mixture, and no solid was precipitated. The mixture was extracted with DCM (40 mL), dried and concentrated with MgSO4 to obtain 1.09 g of a colorless oil, 92.73%.

[0297] 1H NMR (400MHz, CDCl3) δ (ppm) 7.48 (s, 1H), 7.18 (s, 1H), 5.44 (t, J = 5.2Hz, 1H), 4.05 (s ,2H),3.75–3.59(m,2H),3.37(s,3H),3.11(t,J=6.0Hz,2H),2.89(t,J=6.0Hz,2H).

[0298] (11) Synthesis of 1-(methoxymethyl)-6-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Example 20)

[0299]

[0300] Intermediate 18 (76 mg, 0.325 mmol), Pd(OAc)2 (4 mg, 0.016 mmol), X-Phos (16 mg, 0.032 mmol), Cs2CO3 (212 mg, 0.065 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and p-bromotrifluoromethylbenzene (91 μL, 0.651 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 3.5 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, the filtrate was concentrated, and column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 20%) was performed to obtain 62 mg of a yellow solid with a yield of 50.43% and a melting point of 139-141°C.

[0301] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.73 (s, 1H), 7.55 (d, J = 8.0Hz, 2H), 7.36 (s, 1H), 7.05 (d, J = 8.8Hz, 2H), 5.53 (t, J = 5.2Hz, 1H), 4.60 (s, 2H) ,3.80(dd,J1=10.4Hz,J2=5.2Hz,1H),3.74(dd,J1=10.4Hz,J2=4.8Hz,1H),3.69(t,J=6.0Hz,2H),3.43(s,3H),3.18(t,J=6.0Hz,2H); 13C NMR (150MHz, DMSO-d6) δ (ppm) 169.76, 151.78, 145.60, 142.38, 136.09, 126.26 (q, J = 3.8Hz), 125.11 (q, J = 268.7Hz), 123. 88,122.92,122.37,116.85(q,J=31.8Hz),113.03,79.85,72.28,58.63,48.24,44.18,28.58; HR-MS(ESI):m / z,calcd.For C 20 H 19 O3NF3[M+H] + 378.1311,Found:378.1321.

[0302] Embodiment 21:

[0303] Synthesis of 1-(Methoxymethyl)-6-(6-methoxypyridin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0304]

[0305] Intermediate 18 (90 mg, 0.386 mmol), Pd(OAc)2 (5 mg, 0.019 mmol), X-Phos (18 mg, 0.038 mmol), Cs2CO3 (251 mg, 0.77 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 2-bromo-6-methoxypyridine (94 μL, 0.77 mmol) were added, Ar was protected, the tube was sealed and reacted at 100°C for 12 h. After the reaction was completed, the mixture was filtered through celite, concentrated, and purified by column chromatography (SiO2, DCM / EA, EA=0-20%) to obtain 73 mg of a yellow semisolid with a yield of 55.75% and a melting point of 108-110°C.

[0306] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.74 (s, 1H), 7.45 (t, J = 8.0Hz, 1H), 7.32 (s, 1H), 6.22 (d, J = 8.0Hz, 1H), 6.10 (d, J = 7.6Hz, 1H), 5.52 (t, J = 5.2Hz,1H),4.80(s,2H),3.91(s,3H),3.88(t,J=5.9Hz,2H),3.76(dd,J1=5.2Hz,J2=2.4Hz,2H),3.43(s,3H),3.10(t,J=6.0Hz,2H); 13C NMR(150MHz,DMSO-d6)δ(ppm)169.78,162.41,156.92,145.37,142.66,140.43,136.44,123.83,122.8 1,122.59,98.03,97.14,79.81,72.31,58.62,52.49,46.50,41.69,28.63; HR-MS(ESI):m / z,calcd.For C 19 H 21 O4N2[M+H] + 341.1496,Found:341.1503.

[0307] Embodiment 22:

[0308] Synthesis of 6-(3,4-difluorophenyl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0309]

[0310] Intermediate 18 (90 mg, 0.385 mmol), Pd(OAc)2 (4 mg, 0.019 mmol), X-Phos (18 mg, 0.038 mmol), Cs2CO3 (251 mg, 0.77 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and 3,4-difluorobromobenzene (87 μL, 0.77 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 6.5 h. After the reaction was completed, celite was filtered, the filtrate was concentrated, column chromatography (SiO2, DCM / EA, EA=10%), concentrated, and washed with anhydrous ether to obtain 69 mg of a yellow solid with a yield of 51.79% and a melting point of 110-112°C.

[0311] 1 H NMR(400MHz, CDCl3)δ(ppm)7.70(s,1H),7.33(s,1H),7.12–7.05(m,1H),6.83–6.77(m,1H),6.69–6.64(m,1H),5.52(t, J=4.8Hz,1H),4.44(s,2H),3.78(dd,J1=10.4Hz,J2=5.6Hz,1H),3.74(dd,J1=10.8Hz,J2=5.2Hz,1H),3.54(t,J=5.6Hz, 2H), 3.44 (s,3H), 3.14 (t, J = 6.0 Hz, 2H); 13C NMR (150 MHz, CDCl3) δ (ppm) 170.04, 150.74 (dd, J1 = 244.4Hz, J2 = 13.1Hz), 147.07 (d, J = 7.7Hz), 145. 72,144.09(dd,J1=238.7Hz,J2=12.9Hz),141.94,136.00,124.62,123.69,122 .47,117.49(d,J=17.6Hz),110.68(dd,J1=5.55Hz,J2=3.15Hz),104.58(d,J=2 0.4Hz),79.54,73.44,59.78,51.16,46.70,29.77; HR-MS(ESI):m / z,calcd.For C 19 H 18 O3NF2[M+H] + 346.1249,Found:346.1252.

[0312] Embodiment 23:

[0313] Synthesis of 6-(3-chlorophenyl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0314]

[0315] Intermediate 18 (100 mg, 0.528 mmol), Pd(OAc)2 (4 mg, 0.019 mmol), X-Phos (18 mg, 0.038 mmol), Cs2CO3 (251 mg, 0.77 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and m-chlorobromobenzene (91 μL, 0.77 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 2.5 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, concentrated, and chromatographed on a column (SiO2, DCM / EA, EA=20%), concentrated, and washed with anhydrous ether to obtain 83 mg of a yellow semisolid with a yield of 62.57% and a melting point of 70-72°C. 1H NMR (400MHz, CDCl3) δ (ppm) 7.71 (s, 1H), 7.32 (s, 1H), 7.20 (t, J = 8.0Hz, 1H), 6.91 (t, J = 2.4Hz, 1H), 6.85–6.75 (m, 2H), 5.52 (t, J = 5 .2Hz,1H),4.50(s,2H),3.82–3.70(m,2H),3.59(t,J=5.8Hz,2H),3.43(s,3H),3.11(t,J=5.8Hz,2H); HR-MS(ESI):m / z,calcd.For C 19 H 19 O3NCl[M+H] + 344.1048,Found:344.1053.

[0316] Embodiment 24:

[0317] Synthesis of 1-(Methoxymethyl)-6-(quinolin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0318]

[0319] Intermediate 18 (100 mg, 0.342 mmol), Pd(OAc)2 (4 mg, 0.017 mmol), X-Phos (16 mg, 0.034 mmol), Cs2CO3 (223 mg, 0.685 mmol), 2-bromoquinoline (142 mg, 0.685 mmol) were placed in a 25 mL two-necked round-bottom flask, and then 1,4-dioxane 6.0 mL was added. Ar protection was performed, and the reaction was refluxed in an oil bath for 6 h. After the reaction was completed, the filtrate was filtered on diatomaceous earth, and the filtrate was concentrated and subjected to column chromatography (SiO2, DCM / EA, EA=8-10%) for multiple times, and concentrated to obtain 10 mg of a yellow solid with a yield of 10.79% and a melting point of 138-140°C.

[0320] 1H NMR(400MHz,DMSO-d6)δ(ppm)8.10(d,J=8.8Hz,1H),7.79(s,1H),7.72(d,J=7.6Hz,1H),7.62 (d,J=8.4Hz,1H),7.56–7.52(m,2H),7.32(d,J=9.2Hz,1H),7.23(d,J=7.6Hz,1H),5.72(t,J= 4.4Hz,1H),5.01(s,2H),4.00(t,J=6.0Hz,2H),3.87(dd,J1=11.6Hz,J2=3.2Hz,1H),3.70(dd ,J1=11.2Hz, J2=5.2Hz,1H),3.25(s,3H),3.11(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 22 H 21 O3N2[M+H] + 361.1547,Found:361.1537.

[0321] Embodiment 25:

[0322] Synthesis of 6-(Benzo[b]thiophen-5-yl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0323]

[0324] Intermediate 18 (95 mg, 0.407 mmol), Pd(OAc)2 (9 mg, 0.040 mmol), X-Phos (39 mg, 0.080 mmol), Cs2CO3 (265 mg, 0.814 mmol), 5-bromobenzo[b]thiophene (174 mg, 0.814 mmol) were placed in a 25 mL two-necked round-bottom flask, and 7.0 mL of 1,4-dioxane was added. Ar protection was performed, and the reaction was refluxed in an oil bath for 3 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, and the filtrate was concentrated and subjected to column chromatography (SiO2, DCM / EA, EA=4%) for multiple times to obtain 53 mg of a brown-yellow solid with a yield of 45% and a melting point of 100-102°C. 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.83 (d, J = 8.8 Hz, 1H), 7.75 (s, 1H), 7.66 (d, J = 5.2 Hz, 1H), 7.50 (s, 1H),7.43(d,J=2.4Hz,1H),7.32(d,J=6.0Hz,1H),7.22(dd,J1=8.8Hz,J2=2.4Hz,1H),5.71(dd,J1 =5.2Hz,J2=3.2Hz,1H),4.56(s,2H),3.87(dd,J1=11.2Hz,J2=3.2Hz,1H),3.69(dd,J1=11.2Hz,J 2=5.2Hz,1H),3.68–3.56(m,2H),3.26(s,3H),3.09(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 21 H 20 O3NS[M+H] + 366.1158,Found:366.1154.

[0325] Embodiment 26:

[0326] Synthesis of 6-(Benzo[b]thiophen-6-yl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0327]

[0328] Intermediate 18 (90 mg, 0.386 mmol), Pd(OAc)2 (90 mg, 0.039 mmol), X-Phos (37 mg, 0.770 mmol), Cs2CO3 (251 mg, 0.771 mmol), 6-bromobenzo[b]thiophene (166 mg, 0.771 mmol) were placed in a 25 mL two-necked round-bottom flask, and 7.0 mL of 1,4-dioxane was added. Ar protection was performed, and the reaction was refluxed in an oil bath for 4 h. After the reaction was completed, the filtrate was filtered on diatomaceous earth, and the filtrate was concentrated. The filtrate was chromatographed twice (SiO2, DCM / EA, EA=4%), and concentrated to obtain 90 mg of a yellow solid, which was washed with anhydrous ether to obtain 62 mg of a light yellow solid, with a yield of 44.68%, and a melting point of 105-107°C.

[0329] 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.70 (s, 1H), 7.68 (d, J = 8.8Hz, 1H), 7.49 (d, J = 2.4Hz, 1H), 7 .46(s,1H),7.37(d,J=5.2Hz,1H),7.23(J=5.6Hz,1H),7.16(dd,J1=8.8Hz,J2=2.4Hz,1H) ,5.66(dd,J1=5.2Hz,J2=3.2Hz,1H),4.54(s,2H),3.83(dd,J1=11.2Hz,J2=3.2Hz,1H),3. 65(dd,J1=11.2Hz, J2=5.2Hz,1H),3.62–3.58(m,2H),3.21(s,3H),3.04(t,J=6.0Hz,2H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)169.81,147.40,145.27,142.10,141.00,136.45,131.83,123.79,123.71,123.42, 123.22,122.97,122.59,114.60,106.88,79.82,72.34,57.69,51.77,46.73,28.74; HR-MS(ESI):m / z,calcd.For C 21 H 20 O3NS[M+H] + 3666.1158,Found:366.1155.

[0330] Embodiment 27:

[0331] Synthesis of 6-(Benzofuran-5-yl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0332]

[0333] Intermediate 18 (95 mg, 0.407 mmol), Pd(OAc)2 (9 mg, 0.040 mmol), X-Phos (39 mg, 0.080 mmol), Cs2CO3 (265 mg, 0.814 mmol), 5-bromobenzofuran (102 μL, 0.814 mmol) were placed in a 25 mL two-necked round-bottom flask, and 7.0 mL of 1,4-dioxane was added. Ar protection was performed, and the reaction was refluxed in an oil bath for 12 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, and the filtrate was concentrated and subjected to column chromatography (SiO2, DCM / EA, EA=4%). The filtrate was concentrated to obtain 70 mg of an off-white solid with a yield of 49.21% and a melting point of 127-129°C.

[0334] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.89 (d, J=2.4Hz, 1H), 7.72 (s, 1H), 7.49 (s, 1H), 7.47 (d, J= 8.8Hz,1H),7.21(d,J=2.4Hz,1H),7.11(dd,J1=8.8Hz,J2=2.4Hz,1H),6.84(d,J=2.4Hz,1 H),5.71(dd,J1=4.8Hz,J2=2.8Hz,1H),4.48(s,2H),3.87(dd,J=11.2Hz,J=2.8Hz,1H),3. 69(dd,J1=11.2Hz, J2=5.2Hz,1H),3.59–3.52(m,2H),3.26(s,3H),3.08(t,J=5.8Hz,2H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)169.82,148.97,146.74,146.19,145.14,141.95,136.60,127.76,123.66,122.95, 122.63,115.07,111.37,107.06,106.72,79.81,72.37,58.62,51.64,47.45,28.97; HR-MS(ESI):m / z,calcd.For C 21 H 20 O4N[M+H] + 350.1387,Found:350.1377.

[0335] Embodiment 28:

[0336] Synthesis of 6-(Benzofuran-6-yl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0337]

[0338] Intermediate 18 (90 mg, 0.386 mmol), Pd(OAc)2 (9 mg, 0.038 mmol), X-Phos (37 mg, 0.077 mmol), Cs2CO3 (251 mg, 0.771 mmol), 6-bromobenzofuran (95 μL, 0.771 mmol) were placed in a 25 mL two-necked round-bottom flask, and 7.0 mL of 1,4-dioxane was added. Ar protection was performed, and the reaction was refluxed in an oil bath for 3 h. After the reaction was completed, the filtrate was filtered on diatomaceous earth, and the filtrate was concentrated and subjected to column chromatography (SiO2, DCM / EA, EA=2%-4%). ​​The filtrate was concentrated to obtain 65 mg of a light yellow solid with a yield of 48.22% and a melting point of 120-122°C. 1 H NMR(400MHz,DMSO-d6)δ(ppm)7.78–7.77(m,1H),7.75(s,1H),7.52–7.46(m,2H),7.18 (s,1H),7.05(dd,J1=8.0Hz,J2=1.2Hz,1H),6.80(d,J=2.0Hz,1H),5.71–5.70(m,1H),4 .55(s,2H),3.87(dd,J1=11.2Hz,J2=3.6Hz,1H),3.69(dd,J1=11.2Hz,J2=4.4Hz,1H), 3.62(t,J=6.0Hz,2H),3.26(s,3H),3.06(t,J=6.0Hz,2H); HR-MS(ESI):m / z,calcd.For C 21 H 20 O4N[M+H] + 350.1387,Found:350.1385.

[0339] Embodiment 29:

[0340] Synthesis of 6-(isoquinolin-6-yl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0341]

[0342] Intermediate 18 (60 mg, 0.257 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.052 mmol), Cs2CO3 (167 mg, 0.514 mmol), 6-bromoquinoline (107 mg, 0.514 mmol) were placed in a 25 mL two-necked round-bottom flask, and 1,4-dioxane 6.0 mL was added. Ar protection was applied, the tube was sealed and heated at 100°C for 12 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, and the filtrate was concentrated and subjected to column chromatography (SiO2, DCM / MeOH, MeOH=2-6%) for multiple times. The filtrate was concentrated to obtain 42 mg of a yellow solid with a yield of 45.31% and a melting point of 102-104°C.

[0343] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 8.96 (s, 1H), 8.23 ​​(s, 1H), 7.91 (d, J = 9.2Hz, 1H), 7.75 (s ,1H),7.58–7.47(m,3H),7.12(d,J=2.4Hz,1H),5.68(dd,J1=5.2Hz,J2=3.2Hz,1H),4. 71(s,2H),3.83(dd,J1=12.4Hz,J2=4.0Hz,1H),3.73(t,J=6.0Hz,2H),3.66(dd,J1=11 .2Hz, J2=4.8Hz, 1H), 3.21 (s, 3H), 3.09 (t, J=6.0Hz, 2H); HR-MS (ESI): m / z, calcd.For C 22 H 21 O3N2[M+H] + 361.1547,Found:361.1538.

[0344] Embodiment 30:

[0345] Synthesis of 6-(Benzo[d][1,3]dihydroxy-5-yl)-1-methyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0346]

[0347] (1) Synthesis of 2-(tert-butyl)-7-methyl-6-formyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate (Intermediate 19)

[0348]

[0349] NaIO4 (5.07 g, 23.50 mmol) and K2O4Os 2H2O (549 mg, 1.76 mmol) were dissolved in 40 mL of water, placed at -10°C, and a solution of intermediate 14 (3.73 g, 11.75 mmol) in ACN (40 mL) was added dropwise. After the addition was completed, the temperature was gradually raised to 0°C and the reaction was continued for 40 min. After the reaction was completed, diatomaceous earth was filtered, the filtrate was diluted with EA (100 mL), the organic layer was washed with saturated sodium chloride (50 mL), dried with MgSO4, filtered and concentrated. Purification by column chromatography (SiO2, PE / EA, EA=14%) gave 1.25 g of a white solid with a yield of 33.54% and a melting point of 130-132°C.

[0350] 1 H NMR (400MHz, CDCl3) δ (ppm) 10.61 (s, 1H), 7.75 (s, 1H), 7.74 (s, 1H), 4.66 (s, 2H),3.97(s,3H),3.68(t,J=6.0Hz,2H),2.93(t,J=6.0Hz,2H),1.50(s,9H).

[0351] (2) Synthesis of tert-butyl 1-methyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 20)

[0352]

[0353] Intermediate 19 (612 mg, 1.92 mmol) was dissolved in THF, Ar protected, and methylmagnesium bromide (1.1 mL, 2.31 mmol) in ether (3 M) was added dropwise. The reaction was allowed to react for 2 h in an ice-water bath, and the reaction was stopped. Water was added to quench the reaction, and the reaction was extracted with DCM (20 ml), washed with saturated NH4Cl (20 ml), washed with saturated NaCl (30 ml), dried over anhydrous MgSO4, and filtered. Purification by column chromatography (SiO2, PE / EAEA=16%) gave 420 mg of a white solid, with a yield of 72.75%, and a melting point of 121-123°C.

[0354] 1 H NMR (500MHz, CDCl3) δ (ppm) 7.64 (s, 1H), 7.20 (s, 1H), 5.51 (q, J = 6.5Hz, 1H), 4.66 (s, 2H),3.68(t,J=6.0Hz,2H),2.96(t,J=6.0Hz,2H),1.61(d,J=7.0Hz,3H),1.50(s,9H); 13C NMR(150MHz,DMSO-d6)δ(ppm)170.19,154.69,149.41,142.21,135.45,124.15,123.41,121.70 ,80.28,77.46,45.99(45.35),41.35(40.31),29.95,28.45,20.55; HR-MS(ESI):m / z,calcd.For C 13 H 14 O4N[(M-C4H9)+H] + 248.0917,Found:248.0929.

[0355] (3) Synthesis of 1-methyl-5,6,7,8-tetrahydrofuro[3,4-g]isoquinolin-3(1H)-one (Intermediate 21)

[0356]

[0357] Intermediate 20 (315 mg, 1.04 mmol) was dissolved in anhydrous DCM (8 mL), trifluoroacetic acid (1.59 mL, 20.77 mmol) was added under ice-water bath conditions, and stirred for 1 h. The mixture was concentrated, and the excess trifluoroacetic acid was removed by spin drying with a small amount of DCM several times, and then a large amount of ammonia water was added for alkalization, and extracted with DCM (20 mL), dried over MgSO4, filtered and concentrated to obtain 190 mg of an off-white semi-solid with a yield of 90.5%.

[0358] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.54 (s, 1H), 7.14 (s, 1H), 5.50 (q, J = 6.8Hz, 1H), 4. 12(s,2H),3.18(t,J=6.2Hz,2H),2.94(t,J=5.8Hz,2H),1.60(d,J=6.8Hz,3H).

[0359] (4) Synthesis of 6-(Benzo[d][1,3]dihydroxy-5-yl)-1-methyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Example 30)

[0360]

[0361] Intermediate 21 (100 mg, 0.492 mmol), Pd(OAc)2 (5 mg, 0.024 mmol), X-Phos (23 mg, 0.049 mmol), Cs2CO3 (320 mg, 0.984 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 8.0 mL and 1-bromo-3,4-(methylenedioxy)benzene (197 μL, 0.984 mmol) were added, Ar was protected, and the tube was sealed and heated at 100°C in a sand bath for 5.0 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, concentrated, and washed with anhydrous ether several times to obtain 57 mg of a yellow solid with a yield of 20% and a melting point of 150-152°C.

[0362] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.65 (s, 1H), 7.20 (s, 1H), 6.75 (d, J = 8.4Hz, 1H), 6.63 (s, 1H), 6.44 (d, J = 8.4Hz, 1H), 5.92 (s, 2H), 5.5 2(q,J=6.8Hz,1H),4.37(s,2H),3.47(t,J=6.0Hz,2H),3.11(t,J=6.0Hz,2H),1.63(d,J=6.4Hz,3H); HR-MS(ESI):m / z,calcd.For C 19 H 18 O4N[M+H] + 324.1230,Found:324.1241.

[0363] Embodiment 31:

[0364] Synthesis of 6-(Benzofuran-5-yl)-1-methyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0365]

[0366] Intermediate 21 (70 mg, 0.344 mmol), Pd(OAc)2 (8 mg, 0.034 mmol), X-Phos (33 mg, 0.068 mmol), Cs2CO3 (224 mg, 0.688 mmol), 5-bromobenzofuran (82 μL, 0.688 mmol) were placed in a 25 mL two-necked round-bottom flask, and 1,4-dioxane 7.0 mL was added. Ar protection was applied, and the mixture was heated under reflux in an oil bath for 12 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, the filtrate was concentrated, and column chromatography (SiO2, DCM / EA, EA=4%) was performed, and the mixture was concentrated to obtain 40 mg of an off-white solid with a yield of 49.21% and a melting point of 164-166°C.

[0367] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.89 (d, J = 2.0Hz, 1H), 7.72 (s, 1H), 7.52–7.44 (m, 2H), 7.21 (d, J = 2.4Hz, 1H), 7.11 (dd, J1 = 9.2, J2 = 2.4Hz, 1H), 6.8 5–6.83(m,1H),5.65(q,J=6.8Hz,1H),4.48(s,2H),3.64–3.48(m,2H),3.08(t,J=6.0Hz,2H),1.54(d,J=6.4Hz,3H); HR-MS(ESI):m / z,calcd.For C 20 H 18 O4N2[M+H] + 320.1281,Found:320.1278.

[0368] Embodiment 32:

[0369] Synthesis of 6-(Benzofuran-6-yl)-1-methyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0370]

[0371] Intermediate 21 (60 mg, 0.295 mmol), Pd(OAc)2 (6 mg, 0.030 mmol), X-Phos (28 mg, 0.059 mmol), Cs2CO3 (192 mg, 0.590 mmol), 6-bromobenzofuran (73 μL, 0.590 mmol) were placed in a 25 mL two-necked round-bottom flask, and 1,4-dioxane 7.0 mL was added. Ar protection was applied, and the mixture was heated under reflux in an oil bath for 2 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated and subjected to column chromatography (SiO2, DCM / EA, EA=2%-4%). ​​The mixture was concentrated to give 32 mg of a light yellow solid with a yield of 38.22% and a melting point of 164-166°C. 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.73 (d, J = 2.0Hz, 1H), 7.70 (s, 1H), 7.45–7.42 (m, 2H), 7.14 (s, 1H), 7.01 (dd, J1 = 8.8Hz, J2 = 2.2Hz, 1H), 6.75 (d, J=2.4Hz,1H),5.60(q,J=6.8Hz,1H),4.51(s,2H),3.63–3.50(m,2H),3.03(t,J=6.0Hz,2H),1.49(d,J=6.4Hz,3H); HR-MS(ESI):m / z,calcd.For C 20 H 18 O3N[M+H] + 320.1281,Found:320.1279.

[0372] Embodiment 33:

[0373] Synthesis of 6-(4-chlorophenyl)-1-methyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)one

[0374]

[0375] Intermediate 21 (90 mg, 0.442 mmol), p-chlorobromobenzene (169 mg, 0.885 mmol), Pd2(dba)3 (42 mg, 0.088 mmol), X-Phos (40 mg, 0.044 mmol), Cs2CO3 (288 mg, 0.885 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 8 mL was added, Ar was protected, and the reaction was heated under reflux for 4 h. After the reaction was completed, the mixture was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated. Column chromatography purification (SiO2, PE / EA, EA=20%) gave 79 mg of a light yellow solid with a yield of 56.86% and a melting point of 135-137°C. 1H NMR (500MHz, DMSO-d6) δ (ppm) 7.71 (s, 1H), 7.48 (s, 1H), 7.24 (d, J = 6.8Hz, 2H), 7.00 (d,J=6.8Hz,2H),5.66–5.61(m,1H),4.51(s,2H),3.59–3.53(m,2H),3.06–3.01(m, 2H), 1.53 (d, J = 6.4 Hz, 3H); 13 C NMR (150 MHz, CDCl3) δ (ppm)170.14,149.71,145.77,141.62,135.09,129.36,124.24,123.63,121.66, 120.25,117.19,77.51,51.34,47.07,29.39,20.53; HR-MS(ESI):m / z,calcd.For C 18 H 17 O2NCl[M+H] + 314.0942,Found:314.0948.

[0376] Embodiment 34:

[0377] Synthesis of 6-(6-methoxypyridin-2-yl)-1-methyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0378]

[0379] Intermediate 21 (90 mg, 0.442 mmol), Pd(OAc)2 (5 mg, 0.022 mmol), X-Phos (22 mg, 0.044 mmol), Cs2CO3 (216 mg, 0.66 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 2-bromo-6-methoxypyridine (108 μL, 0.885 mmol) were added, Ar was protected, the tube was sealed and reacted at 103°C for 12 h. After the reaction was completed, celite was filtered, concentrated, and purified by column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 2%-8%) to obtain 78 mg of a yellow solid with a yield of 56.76% and a melting point of 138-140°C. 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.74 (s, 1H), 7.51 (s, 1H), 7.48 (t, J = 8.0Hz, 1H), 6.36 (d, J = 8.0Hz, 1H), 6.04 (d, J = 7.8Hz,1H),5.65(q,J=6.6Hz,1H),4.79(s,2H),3.87–3.78(s,5H),3.05(t,J=6.0Hz,2H),1.54(d,J=6.6Hz,3H); 13 C NMR (150MHz, CDCl3) δ (ppm) 170.28,163.11,156.70,149.56,142.68,140.62,135.90,124.09,123 .58,121.50,98.47,98.05,77.50,53.36,47.54,42.71,29.65,20.55; HR-MS(ESI):m / z,calcd.For C 18 H 19 O3N2[M+H] + 311.1390,Found:311.1396.

[0380] Embodiment 35:

[0381] Synthesis of 6-(3,4-difluorophenyl)-1-(methoxymethyl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0382]

[0383] Intermediate 21 (67 mg, 0.305 mmol), Pd(OAc)2 (3 mg, 0.015 mmol), X-Phos (15 mg, 0.030 mmol), Cs2CO3 (198 mg, 0.61 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and 3,4-difluorobromobenzene (69 μL, 0.61 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 4.5 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, concentrated, and chromatographed on a column (SiO2, DCM / EA, EA=20%), concentrated, and washed with anhydrous ether to obtain 60 mg of a yellow solid with a yield of 62.38% and a melting point of 145-147°C.

[0384] 1H NMR(400MHz, CDCl3)δ(ppm)7.68(s,1H),7.23(s,1H),7.12–7.05(m,1H),6.81–6.75(m,1H),6.68–6.64(m,1 H),5.54(t,J=6.6Hz,1H),4.44(s,2H),3.55(t,J=6.0Hz,2H),3.13(t,J=5.8Hz,2H),1.63(d,J=6.6Hz,3H); 13 C NMR (150MHz, CDCl3) δ (ppm) 170.21, 150.72 (dd, J1=244.4Hz, J2=13.2Hz), 149.61, 147.07(d,J=8.1Hz),144.08(dd,J1=238.4Hz,J2=12.6Hz),141.87,135.55,124.1 3,123.60,121.61,117.47(d,J=17.4Hz),110.68(dd,J1=4.5Hz,J2=3.75Hz),104. 58(d,J=20.4Hz),77.50,51.13,46.74,29.74,20.54; HR-MS(ESI):m / z,calcd.For C 18 H 16 O2NF2[M+H] + 316.1144,Found:316.1146.

[0385] Embodiment 36:

[0386] Synthesis of 6-(3,4-difluorophenyl)-1-ethyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0387]

[0388] (1) Synthesis of tert-butyl 1-ethyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 22)

[0389]

[0390] Intermediate 19 (592 mg, 1.82 mmol) was dissolved in THF (25 mL), and Ar was protected. Ethyl magnesium bromide (1.05 mL, 3.15 mmol) in ether (3 M) was added dropwise under ice-water bath. After the addition was complete, the mixture was heated to room temperature and reacted for 3 h. The reaction was stopped, quenched with water (10 mL), extracted with DCM (20 mL), and the organic phase was washed with saturated NH4Cl (10 mL), saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated. Purified by column chromatography (SiO2, PE / EA, EA=16%), 311 mg of a white solid was obtained, with a yield of 52.95%, and a melting point of 135-137°C.

[0391] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.63 (s, 1H), 7.18 (s, 1H), 5.38 (dd, J1 = 7.2Hz, J2 = 4.4Hz, 1H), 4.65 (s, 2H), 3.67 (t, J = 6.0Hz, 2H), 2.95(t,J=6.0Hz,2H),2.14–2.04(m,1H),1.84–1.75(m,1H),1.48(s,9H),0.98(t,J=9.2Hz,3H); HR-MS(ESI):m / z,calcd.ForC 14 H 16 O4N[(M-C4H9)+H] + 262.1074,Found:262.1062.

[0392] (2) Synthesis of 1-ethyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Intermediate 23)

[0393]

[0394] Intermediate 22 (295 mg, 0.929 mmol) was dissolved in anhydrous DCM (10 mL), trifluoroacetic acid (1.49 mL, 18.59 mmol) was added in an ice-water bath, and stirred in an ice-water bath for 1 h. The solvent was spin-dried, and a small amount of DCM was used to spin-dry several times to remove the excess trifluoroacetic acid. A large amount of ammonia was then added to alkalize, and DCM (10 mL) was used for extraction, and MgSO4 was dried and concentrated to obtain 167 mg of an off-white semi-solid with a yield of 82.70%.

[0395] 1H NMR (400MHz, CDCl3) δ (ppm) 7.54 (s, 1H), 7.14 (s, 1H), 5.39 (dd, J1 = 7.2Hz, J2 = 4.0Hz, 1H), 4.12 (s, 2H), 3.19 (t, J=6.0Hz,2H),2.96(d,J=6.0Hz,2H),2.22(s,1H),2.13-2.03(m,1H),1.89–1.75(m,1H),0.99(t,J=7.6Hz,3H).

[0396] (3) Synthesis of 6-(3,4-difluorophenyl)-1-ethyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Example 36)

[0397]

[0398] Intermediate 23 (84 mg, 0.386 mmol), Pd(OAc)2 (5 mg, 0.019 mmol), X-Phos (19 mg, 0.039 mmol), Cs2CO3 (252 mg, 0.73 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and 3,4-difluorobromobenzene (88 μL, 0.73 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 2.5 h. After the reaction was completed, celite was filtered, the filtrate was concentrated, column chromatography (SiO2, DCM / EA, EA=18%-20%), concentrated, and washed with anhydrous ether to obtain 92 mg of an off-white solid with a yield of 65.85% and a melting point of 105-107°C.

[0399] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.68 (s, 1H), 7.22 (s, 1H), 7.11–7.04 (m, 1H), 6.79–6.73 (m, 1H), 6.69–6.60 (m, 1H), 5.42 (dd, J1=7.2Hz, J2=4.8Hz, 1H), For C 19 H 18 O2NF2[M+H] + 330.1300,Found:330.1296.

[0400] Embodiment 37:

[0401] Synthesis of 1-ethyl-6-(6-methoxypyridin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0402]

[0403] Intermediate 23 (84 mg, 0.386 mmol), Pd(OAc)2 (5 mg, 0.019 mmol), X-Phos (18 mg, 0.037 mmol), Cs2CO3 (251 mg, 0.77 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 2-bromo-6-methoxypyridine (95 μL, 0.77 mmol) were added, Ar was protected, the tube was sealed and reacted at 100°C for 12 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, and the filtrate was concentrated and purified by column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 0%-2%) to obtain 96 mg of a yellow solid, which was washed with anhydrous ether to obtain 76 mg of a light yellow solid, with a yield of 46.55%, and a melting point of 115-117°C.

[0404] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.72 (s, 1H), 7.46 (t, J = 8.0Hz, 1H), 7.22 (s, 1H), 6.25 (d, J = 8.0Hz, 1H), 6.11 (d, J = 8.0Hz, 1H), 5.42– 5.39(m,1H),4.80(s,2H),3.99–3.84(m,5H),3.10(t,J=6.0Hz,2H),2.14–2.05(m,1H),1.87–1.75(m,1H),1.01(t,J=7.4Hz,3H); 13 C NMR(150MHz,DMSO-d6)δ(ppm)169.82,162.41,156.92,147.91,142.78,140.42,136.21,123.46,122.7 8,122.22,98.03,97.11,81.64,52.49,46.48,41.70,28.67,26.92,8.63; HR-MS(ESI):m / z,calcd.For C 19 H 21 O3N2[M+H] + 325.1547,Found:325.1552.

[0405] Embodiment 38:

[0406] Synthesis of 1-ethyl-6-(5-methylpyrimidin-2-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0407]

[0408] Intermediate 23 (94 mg, 0.432 mmol), Pd(OAc)2 (10 mg, 0.043 mmol), X-Phos (41 mg, 0.086 mmol) and Cs2CO3 (282 mg, 0.865 mmol) were placed in a sealed tube, 1,4-dioxane 7.0 mL and 2-bromo-5-methylpyrimidine (150 μL, 0.865 mmol) were added, Ar was protected, the tube was sealed at 95°C, and the reaction was carried out for 12 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, the filtrate was concentrated, and the anhydrous ether was used for multiple pulping and washing to obtain 28 mg of a light yellow solid with a yield of 20.92% and a melting point of 175-177°C.

[0409] 1 H NMR (400MHz, CDCl3) δ (ppm) 8.38 (s, 2H), 7.72 (s, 1H), 7.25 (s, 1H), 5.43 (dd, J1 = 6.8Hz, J2 = 4.4Hz, 1H), 4.52 (s, 2H), 3.62 (t, J = 6.0H z,2H),3.15(t,J=6.0Hz,2H),2.68(s,3H),2.18–2.06(m,1H),1.88–1.76(m,1H),1.01(t,J=7.6Hz,3H); HR-MS(ESI):m / z,calcd.For C 18 H 20 O2N3[M+H] + 310.1550,Found:310.1554.

[0410] Embodiment 39:

[0411] Synthesis of 6-(3,4-difluorophenyl)-1-propyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0412]

[0413] (1) Synthesis of tert-butyl 3-oxo-1-propyl-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 24)

[0414]

[0415] Intermediate 19 (100 mg, 391.41 μmol) was dissolved in THF (5 mL), Ar protected, and propylmagnesium bromide (0.313 mL, 626.26 μmol) in ether (2M) was added. The reaction was reacted in an ice-water bath for 2 h. The reaction was stopped, quenched with water (10 mL), extracted with DCM (10 mL×2), the organic phases were combined, washed with saturated NH4Cl (10 mL), washed with saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated. Purified by column chromatography (SiO2, PE / EA, EA=20%), 65 mg of a white solid was obtained, with a yield of 57.82%, and a melting point of 93-95°C.

[0416] 1 H NMR (400MHz, DMSO-d6) δ (ppm) 7.68 (s, 1H), 7.47 (s, 1H), 5.58 (dd, J1 = 8.0Hz, J2 = 4.0Hz, 1H), 4.61 (s, 2H), 3.56 (t, J = 6.0Hz ,2H),2.93(t,J=6.0Hz,2H),2.03–1.96(m,2H),1.70–1.59(m,1H),1.38(s,9H),1.36–1.20(m,2H),0.92(t,J=7.6Hz,3H); 13 C NMR (150MHz, CDCl3) δ (ppm) 170.40, 154.68, 148.33, 142.06, 135.37, 124.51, 123.40, 121.86, 80.97, 80.27,46.01(45.28),41.38(40.28),36.95,29.95,28.45,18.21,13.80; HR-MS(ESI):m / z,calcd.For C 19 H 26 O4N[M+H] + 332.1856,Found:332.1858.

[0417] (2) Synthesis of 1-propyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Intermediate 25)

[0418]

[0419] Intermediate 24 (200 mg, 0.603 mmol) was dissolved in anhydrous DCM (8 mL), trifluoroacetic acid (92 μL, 12.07 mmol) was added in an ice-water bath, and stirred in an ice-water bath for 1 h. The solvent was spin-dried, and a small amount of DCM was used to spin-dry the excess trifluoroacetic acid several times, and then a large amount of ammonia was added to alkalize, extracted with DCM, and dried with MgSO4 to obtain 123 mg of an off-white semi-solid with a yield of 88.12%.

[0420] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.53 (s, 1H), 7.14 (s, 1H), 5.41 (dd, J1 = 8.0Hz, J2 = 4.0Hz, 1H), 4.11 (s, 2H), 3.18 (t, J = 6.0Hz, 2H),2.94(t,J=6.0Hz,2H),2.05–1.89(m,1H),1.84(s,1H),1.78–1.63(m,1H),1.59–1.39(m,2H),0.97(t,J=7.2Hz,3H).

[0421] (3) Synthesis of 6-(3,4-difluorophenyl)-1-propyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Example 39)

[0422]

[0423] Intermediate 25 (123 mg, 0.531 mmol), Pd(OAc)2 (6 mg, 0.026 mmol), X-Phos (25 mg, 0.053 mmol) and Cs2CO3 (346 mg, 1.06 mmol) were placed in a 25 mL two-necked round-bottom flask, 1,4-dioxane 6.0 mL and 3,4-difluorobromobenzene (120 μL, 1.06 mmol) were added, Ar was protected, and the reaction was refluxed in an oil bath for 3 h. After the reaction was completed, the filtrate was filtered through diatomaceous earth, concentrated, and column chromatographed (SiO2, DCM / EA, EA=20%), concentrated, and washed with anhydrous ether to obtain 128 mg of a light yellow solid with a yield of 70% and a melting point of 80-82°C.

[0424] 1H NMR(400MHz, CDCl3)δ(ppm)7.68(s,1H),7.23(s,1H),7.14–7.03(m,1H),6.79(ddd,J1 =13.2Hz, J2=6.8Hz, J3=3.2Hz, 1H), 6.70–6.64(m, 1H), 5.44(dd, J1=8.0Hz, J2=4.0Hz, 1H),4.44(s,2H),3.54(d,J=6.0Hz,2H),3.13(t,J=6.0Hz,2H),2.09–1.95(m,1H),1.7 9–1.65(m,1H),1.62–1.41(m,2H),1.00(t,J=7.2Hz,3H); HR-MS(ESI):m / z,calcd.ForC 20 H 20 O2NF2[M+H] + 344.1457,Found:344.1465.

[0425] Embodiment 40:

[0426] Synthesis of 1-cyclopropyl-6-(5-fluoropyridin-3-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0427]

[0428] (1) Synthesis of tert-butyl 1-cyclopropyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinoline-6(3H)-carboxylate (Intermediate 26)

[0429]

[0430] Intermediate 19 (125 mg, 391.41 μmol) was dissolved in THF (5 mL), Ar protected, and a THF solution (1 M) of cyclopropylmagnesium bromide (1.57 mL, 782.82 μmol) was added. The reaction was reacted in an ice-water bath for 3 h. The reaction was stopped, quenched with water (10 mL), extracted with DCM (20 mL), and the organic phase was washed with saturated NH4Cl (10 mL), saturated NaCl (10 mL), dried over anhydrous MgSO4, filtered and concentrated. Purified by column chromatography (SiO2, PE / EA, EA=16%), 45 mg of a white solid was obtained, with a yield of 34.90%, and a melting point of 166-168°C. 1H NMR (400MHz, DMSO-d6) δ (ppm) 7.65 (s, 1H), 7.46 (s, 1H), 4.97 (d, J = 8.8Hz, 1H), 4.57 (s, 2H), 3. 52(t,J=6.0Hz,2H),2.91(t,J=6.0Hz,2H),1.39(s,9H),1.07–0.93(m,1H),0.69–0.40(m,4H); 13 C NMR (150MHz, CDCl3) δ (ppm) 170.17, 154.72, 147.90, 142.15, 135.68, 124.54, 123.34, 122.33, 84.95 ,80.31,46.06(45.35),41.41(40.33),29.98,28.48,14.71,2.80,1.94; HR-MS(ESI):m / z,calcd.For C 15 H 16 O4N[(M-C4H9)+H] + 274.1074,Found:274.1088.

[0431] (2) Synthesis of 1-cyclopropyl-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Intermediate 27)

[0432]

[0433] Intermediate 26 (200 mg, 0.607 mmol) was dissolved in anhydrous DCM (8 mL), trifluoroacetic acid (0.93 mL, 12.14 mmol) was added in an ice-water bath, and stirred in an ice-water bath for 1 h. The solvent was spin-dried, and a small amount of DCM was used to spin-dry the excess trifluoroacetic acid several times, and then a large amount of ammonia was added to alkalize, extracted with DCM, dried with MgSO4, filtered and concentrated to obtain 100 mg of a colorless oil with a yield of 71.83%.

[0434] 1 H NMR (400MHz, CDCl3) δ (ppm) 7.53 (s, 1H), 7.24 (s, 1H), 4.78 (d, J = 8.0Hz, 1H), 4.11 (s, 2H), 3.18 (t, J = 6.0 Hz,2H),2.95(t,J=6.0Hz,2H),2.38(brs,1H),1.17–0.98(m,1H),0.76–0.67(m,2H),0.63–0.51(m,2H).

[0435] (3) Synthesis of 1-cyclopropyl-6-(5-fluoropyridin-3-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one (Example 40)

[0436]

[0437] Intermediate 27 (100 mg, 0.436 mmol), Pd(OAc)2 (5 mg, 0.022 mmol), X-Phos (21 mg, 0.044 mmol) and Cs2CO3 (241 mg, 0.74 mmol) were placed in a sealed tube, 1,4-dioxane 6.0 mL and 5-bromo-3-fluoropyridine (90 μL, 0.87 mmol) were added, Ar was protected, the tube was sealed and reacted at 100°C for 12 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, concentrated, and purified by column chromatography (SiO2, DCM / 10% MeOH, 10% MeOH = 2%-9%) to obtain 62 mg of a white solid, which was recrystallized (EA, MeOH, 60°C) to obtain 20 mg of an off-white solid, with a yield of 15.1%, and a melting point of 191-193°C.

[0438] 1 H NMR (400MHz, CDCl3) δ (ppm) 8.18 (s, 1H), 7.96 (s, 1H), 7.72 (s, 1H), 7.37 (s, 1H), 6.99–6.89 (m, 1H), 4.83 (d, J = 8.4Hz, 1H), 4.55 (s, 2H) ),3.65(t,J=6.0Hz,2H),3.16(t,J=6.0Hz,2H),1.22–1.00(m,1H),0.81–0.72(m,2H),0.67–0.61(m,2H); HR-MS(ESI):m / z,calcd.For C 19 H 18 O2N2F[M+H] + 325.1347,Found:325.1354.

[0439] Embodiment 41:

[0440] Synthesis of 1-ethyl-6-(2-methyl-1-oxo-1,2-dihydroisoquinolin-7-yl)-5,6,7,8-tetrahydrofuran[3,4-g]isoquinolin-3(1H)-one

[0441]

[0442] Intermediate 23 (60 mg, 0.276 mmol), Pd(OAc)2 (6 mg, 0.013 mmol), X-Phos (14 mg, 0.0264 mmol), Cs2CO3 (180 mg, 0.552 mmol), 7-bromo-2-methylisoquinolin-1(2H)-one (98 mg, 0.442 mmol) were placed in a 25 mL two-necked round-bottom flask, and 1,4-dioxane 6.0 mL was added. Ar protection was applied, and the mixture was heated under reflux in an oil bath for 2.5 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product. The crude product was subjected to column chromatography (SiO2, PE / EA, EA=36%) and concentrated to obtain 53 mg of a light yellow solid with a yield of 51.26%, 182-184°C.

[0443] 1 H NMR(400MHz, DMSO-d6)δ(ppm)7.76(s,1H),7.59(d,J=2.4Hz,1H),7.53–7.45(m,3H),7.19(d,J=7.2Hz,1H),6.47(d,J=7.2Hz,1H),5.62–5.31 (m,1H),4.59(s,2H),3.63(t,J=6.0Hz,2H),3.44(s,3H),3.07(t,J=6.0Hz,2H),2.12–1.94(m,1H),1.76–1.67(m,1H),0.84(t,J=7.3Hz,3H).

[0444] Embodiment 42:

[0445] Synthesis of 1-methoxymethyl-6-(1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)-5,6,7,8-tetrahydrofuro[3,4-g]isoquinolin-3(1H)-one

[0446]

[0447] (1) Synthesis of tert-butyl 6-bromo-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 28)

[0448]

[0449] 6-Bromo-3,4-dihydroisoquinolin-1(2H)-one (500mg, 2.21mmol), Boc2O (627mg, 2.87mmol) and DMAP (27mg, 0.22mmol) were placed in a 50mL two-necked round-bottom flask, and 20.0mL of DCM was added. Ar protection was applied, and the reaction was refluxed in a sand bath for 2.5h. The reaction was stopped, quenched with water (10mL), extracted with DCM (10mL×2), the organic phases were combined, washed with saturated NH4Cl (10mL), washed with saturated NaCl (10mL), dried over anhydrous MgSO4, filtered and concentrated. Column chromatography (SiO2, PE / EA, EA=8%), concentrated, and 539mg of light yellow solid was obtained, with a yield of 73.47%.

[0450] 1 H NMR (500MHz, CDCl3) δ (ppm) 8.01 (d, J = 9.0Hz, 1H), 7.49 (d, J = 8.5Hz, 1H), 7.39 (s, 1H), 4.05–3.91 (m, 2H), 2.98 (d, J = 6.5Hz, 2H), 1.56 (s, 9H).

[0451] (2) Synthesis of tert-butyl 6-(1-ethyl-3-oxo-1,5,7,8-tetrahydrofuran[3,4-g]isoquinolin-6(3H)-yl)-1-oxo-3,4-dihydroisoquinoline-2(1H)-carboxylate (Intermediate 29)

[0452]

[0453] Intermediate 23 (120 mg, 0.552 mmol), Pd(OAc)2 (12 mg, 0.055 mmol), X-Phos (28 mg, 0.104 mmol) and Cs2CO3 (359 mg, 1.10 mmol), intermediate 28 (361 mg, 1.10 mmol) were placed in a 25 mL two-necked round-bottom flask, and 6.0 mL of 1,4-dioxane was added. Ar protection was applied, and the mixture was heated under reflux in an oil bath for 2.5 h. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated to obtain a crude product, which was then subjected to column chromatography (SiO2, PE / EA, EA=27%) and concentrated to obtain 120 mg of a light yellow solid with a yield of 48.01%.

[0454] 1H NMR(500MHz,DMSO-d6)δ(ppm)7.82(d,J=9.0Hz,1H),7.76(s,1H),7.53(s,1H),6.96(dd ,J1=9.0Hz,J2=2.5Hz,1H),6.81(d,J=2.5Hz,1H),5.57(dd,J1=7.0Hz,J2=4.5Hz,1H),4. 69(s,2H),3.84(d,J=6.0Hz,2H),3.69(t,J=6.0Hz,2H),3.09(t,J=6.0Hz,2H),2.93(t, J=6.2Hz,2H),2.18–1.99(m,1H),1.77–1.71(m,1H),1.48(s,9H),0.88(t,J=7.5Hz,3H).

[0455] (3) Synthesis of 1-methoxymethyl-6-(1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)-5,6,7,8-tetrahydrofuro[3,4-g]isoquinolin-3(1H)-one (Example 42)

[0456]

[0457] Intermediate 29 (90 mg, 188 μmol) was dissolved in DCM (15 mL), and trifluoroacetic acid (114 μL, 1.88 mmol) was added. Ar was protected and the reaction was carried out in an ice-water bath for 0.5 h. After the reaction was completed, a large amount of ether (20 mL) was added, and solids precipitated. 70 mg of gray-yellow solids were obtained by filtration, with a yield of 98.46%, 182-184°C.

[0458] 1 H NMR (500MHz, DMSO-d6) δ (ppm) 7.75 (s, 1H), 7.68 (d, J = 8.5Hz, 1H), 7.52–7.5 1(m,2H),6.91(d,J=8.5Hz,1H),6.83(s,1H),5.66–5.47(m,1H),4.64(s,2H ),3.66(t,J=6.0Hz,2H),3.39–3.28(m,2H),3.08(t,J=6.0Hz,2H),2.83(t, J=6.0Hz,2H),2.15–2.00(m,1H),1.83–1.66(m,1H),0.87(t,J=7.5Hz,3H).

[0459] Pharmacological experiments:

[0460] 1. IC of compounds for inhibition of rat MAO-B / A 50 value

[0461] 1.1 Experimental Grouping

[0462] Negative control group: 100 μL of 200 μg / mL liver tissue fluid and 2 μL DMSO were added to each well of a 96-well all-black fluorescent ELISA plate;

[0463] Positive drug group: 100 μL of liver tissue fluid and 2 μL of positive drug solution of different concentrations were added to each well of the positive drug reaction well;

[0464] Blank control group: 100 μL PB buffer and 2 μL DMSO were added to each well;

[0465] Drug screening group: 100 μL of liver tissue fluid and different concentrations of compounds were added to each well.

[0466] 1.2 Detection of MAOs activity by Amplex Red fluorescence method

[0467] Cover the 96-well plate with a black plastic plate cover and place it in a 37°C incubator for pre-incubation for 30 minutes. Under light-proof conditions, take a 200μL Amplex Red reagent, a 100μL HRP, and a 200μL benzylamine solution, add them to 9.5mL PB buffer and mix well. Wrap the test tube with tin foil and add 98μL Amplex Red reagent / HRP / benzylamine substrate reaction solution to each well under light-proof conditions (for determination of inhibition of MAO-B activity) or add 98μL Amplex Red reagent / HRP / tyramide substrate reaction solution to each well under light-proof conditions (for determination of inhibition of MAO-A activity). Keep the 96-well plate in a 37°C incubator, cover it, and incubate it for 30 minutes in light-proof conditions. Use a fluorescence microplate reader and set the relevant parameters to 560±10nm excitation light and 590±10nm emission light conditions to detect the fluorescence value of each well.

[0468] 1.3 Statistical analysis

[0469] Calculation of compound inhibition rate:

[0470] Negative control group: (average value of positive drug safinamide group - average value of negative control group) / (average value of blank control group - average value of negative control group) × 100%

[0471] Drug screening group: (average value of compound group - average value of negative control group) / (average value of blank control group - average value of negative control group) × 100%

[0472] To calculate the IC of compounds for inhibition of MAO-B / A 50 At least 7-8 concentrations were selected for each compound, with at least n = 3 for each concentration, and IC was fitted using GraphPad Prism 5. 50.

[0473] The experimental results are shown in Table 1

[0474] Table 1. IC values ​​of compounds for inhibition of MAO-B and MAOA 50

[0475]

[0476]

Claims

1. A compound as shown in general formula I or a pharmaceutically acceptable salt thereof In Formula I, Ar is selected from: (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures: The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)n NRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; wherein the halogen is selected from F; the heteroatom is selected from N, O, S; (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures: wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R5 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F; R1 and R2 are independently selected from H, C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)mCH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein Rw1, Rw2, and Rw3 are independently selected from C1, C2, C3, and C4 straight chain or branched alkyl, and halogen-substituted C1, C2, C3, and C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, and 4; m is selected from 0, 1, and 2; o is selected from 1, 2, 3, 4, and 5; and X is selected from CH2, NH, and O.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that The compound is shown in general formula IA In Formula IA, Ar is selected from: (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures: The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7 Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; The halogen is selected from F; (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures: wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R6 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that The compound is shown in the general formula IB In Formula IB, Ar is selected from: (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures: The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; wherein the halogen is selected from F; (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures: wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R6 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F; R7 is selected from: C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)m CH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein Rw1, Rw2, and Rw3 are independently selected from C1, C2, C3, and C4 straight chain or branched alkyl, and halogen-substituted C1, C2, C3, and C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, and 4; m is selected from 0, 1, and 2; o is selected from 1, 2, 3, 4, and 5; and X is selected from CH2, NH, and O.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that The compound is shown in the general formula IC In the IC, Ar is selected from: (1) Substituted or unsubstituted benzene ring, substituted or unsubstituted six-membered aromatic heterocycle, including but not limited to the following structures: The benzene ring and the nitrogen-containing six-membered aromatic heterocycle may be monosubstituted or polysubstituted; the heterocycle may contain one heteroatom or multiple heteroatoms; wherein the substituent R3 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; n is selected from 1, 2, 3; wherein the substituent R4 is selected from C1, C2, C3 straight chain or branched alkyl, halogen-substituted C1, C2, C3 straight chain or branched alkyl; wherein the halogen is selected from F; (2) Substituted or unsubstituted fused heterocycles, including but not limited to the following structures: wherein the substituent R5 is selected from the group consisting of C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl, F, Cl, Br, NO2, CN, ORs1, NRs2Rt1, NRs3CORt2, COORs4, CONRs5Rt3, NRs6COORt4, SO2NRs7Rt5, (CH2)nNRs8Rt6, (CH2)nORs9, wherein the Rs1, Rs2, Rt1, Rs3, Rt2, Rs4, Rs5, Rt3, Rs6, Rt4, Rs7, Rt5, Rs8, Rt6, Rs9 are independently selected from H, methyl, ethyl, cyclopropyl, cyclopropylmethylene, cyclobutyl; wherein the substituent R6 is selected from C1, C2, C3, C4 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4 straight chain or branched alkyl; wherein the fused heterocyclic ring may be monosubstituted or polysubstituted; the fused heterocyclic ring may contain one or more heteroatoms, and the heteroatoms are selected from O, N, S; n is selected from 1, 2, 3; wherein the halogen is selected from F; R8 is selected from: C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, halogen-substituted C1, C2, C3, C4, C5, C6 straight chain or branched alkyl, F, Cl, Br, (CH2)nORw1, CH2CH(CH3)CH2ORw1, (CH2)mCHCH3ORw1, CH2C(CH3)2ORw1, CH2CH(CH2CH3)ORw1, (CH2)nNRw2Rw3, CH2CH(CH3)CH2NRw2Rw3, (CH2)m CH(CH3)NRw2Rw3, CH2C(CH3)2NRw2Rw3, CH2CH(CH2CH3)NRw2Rw3, Wherein Rw1, Rw2, and Rw3 are independently selected from C1, C2, C3, and C4 straight chain or branched alkyl, and halogen-substituted C1, C2, C3, and C4 straight chain or branched alkyl; n is selected from 0, 1, 2, 3, and 4; m is selected from 0, 1, and 2; o is selected from 1, 2, 3, 4, and 5; and X is selected from CH2, NH, and O.

5. The compound according to claim 1-4 or a pharmaceutically acceptable salt thereof, characterized in that The compound is selected from the following group:

6. A compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, characterized in that The pharmaceutically acceptable salts of the compounds are selected from salts formed by combining with inorganic acids, organic acids, alkali metal ions, alkaline earth metal ions or organic bases that can provide physiologically acceptable cations and ammonium salts.

7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, characterized in that The inorganic acid is selected from hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid; the organic acid is selected from methanesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, citric acid, maleic acid, tartaric acid, fumaric acid, citric acid or lactic acid; the alkali metal ion is selected from lithium ion, sodium ion, potassium ion; the alkaline earth metal ion is selected from calcium ion and magnesium ion; the organic base capable of providing physiologically acceptable cations is selected from methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris(2-hydroxyethyl)amine.

8. A method for preparing a compound according to any one of claims 1 to 7, characterized in that The steps include: According to the structure of the 3-substituent (R1, R2), the compound represented by the general formula I is synthesized by the synthesis method of Scheme 1-4; Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a trifluoroacetyl protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 2; Intermediate 2 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 3; Intermediate 3 is reacted with N-formyl saccharin through coupling reaction to prepare intermediate 4; Intermediate 4 undergoes bromination reaction with NBS to obtain intermediate 5; Intermediate 5 was treated with potassium carbonate aqueous solution to remove the trifluoroacetyl group to obtain a compound without substitution on the N-side; a Boc protecting group was introduced to obtain intermediate 6; Intermediate 6 is reduced to give intermediate 7; Intermediate 7 was subjected to carbonyl insertion coupling reaction to give intermediate 8; Intermediate 8 is treated with trifluoroacetic acid or hydrogen chloride in 1,4-dioxane to remove Boc to obtain intermediate 9; Intermediate 9 is subjected to coupling reaction to introduce Ar to obtain a compound of formula IA; Using 1,2,3,4-tetrahydroisoquinolin-6-ol 1 as the starting material, a Boc protecting group was introduced at the 1-position of 1,2,3,4-tetrahydroisoquinolin-6-ol through an acylation reaction to obtain intermediate 10; Intermediate 10 undergoes Friedel-Crafts acylation with paraformaldehyde to prepare intermediate 11; Intermediate 11 is acylated with trifluoromethanesulfonyl chloride to prepare intermediate 12; Intermediate 12 undergoes Pinnick oxidation reaction to obtain intermediate 13; Intermediate 13 undergoes esterification reaction with methyl iodide to obtain intermediate 14; Intermediate 14 undergoes coupling reaction with potassium vinyl trifluoroborate to obtain intermediate 15; Intermediate 15 is subjected to oxidation reaction to obtain intermediate 16; Intermediate 16 undergoes addition reaction with an alkyl Grignard reagent to obtain intermediate 17; Intermediate 17 is treated with trifluoroacetic acid or hydrogen chloride in 1,4-dioxane to remove Boc to obtain intermediate 18; Intermediate 18 is subjected to coupling reaction or substitution reaction to introduce Ar to obtain a compound represented by the general formula IB; Intermediate 15 undergoes hydrolysis to obtain intermediate 19; Intermediate 19 is oxidized to give intermediate 20; Intermediate 20 undergoes substitution reaction with an alkyl halide to give intermediate 21; Intermediate 21 is treated with a 1,4-dioxane solution of trifluoroacetic acid or hydrogen chloride to remove Boc, and Ar is introduced through a coupling reaction or a substitution reaction to obtain a compound of the general formula IB; Intermediate 12 was reacted with triisopropylsilyl acetylene via Sonogashira coupling to prepare key intermediate 22; The silicon protecting group of intermediate 22 was removed by tetrabutylammonium fluoride to obtain intermediate 23; Intermediate 23 undergoes Pinnick oxidation reaction to obtain intermediate 24; Intermediate 24 undergoes hydrolysis to obtain intermediate 25; Intermediate 25 undergoes esterification with methyl iodide to give intermediate 26; Intermediate 26 undergoes nucleophilic addition reaction with alkyl Grignard reagent to give intermediate 27; Intermediate 27 is treated with trifluoroacetic acid or hydrogen chloride in 1,4-dioxane to remove Boc, and Ar is introduced through coupling reaction to obtain a compound represented by general formula IC; The definitions of Ar, R7, and R8 are the same as those of claims 1-7, and R9 is independently selected from C1, C2, C3, and C4 straight-chain or branched alkyl groups, and halogen-substituted C1, C2, C3, and C4 straight-chain or branched alkyl groups.

9. A pharmaceutical composition, characterized in that The invention comprises an effective dose of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof and a pharmacologically acceptable carrier.

10. Use of the compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the preparation of an MAO-B and / or MAO-A inhibitor.

11. Use of a compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing and / or treating diseases associated with MAO-B and / or MAO-A.

12. The use according to claim 11, characterized in that The disease associated with MAO-B and / or MAO-A is selected from psychiatric and nervous system diseases, metabolic diseases, cardiovascular system diseases or cancer.

13. Use according to claim 12, characterized in that The mental and nervous system diseases include Parkinson's disease, senile dementia, Alzheimer's disease, depression, and anxiety.